

NQF 0038: Childhood Immunization Status

Clinical Quality Measure Quick Reference Guide and Technical Supplement

Provided By:

The National Learning Consortium (NLC)

Developed By:

Health Information Technology Research Center (HITRC)

The material in this document was developed by Regional Extension Center staff in the performance of technical support and EHR implementation. The information in this document is not intended to serve as legal advice nor should it substitute for legal counsel. Users are encouraged to seek additional detailed technical guidance to supplement the information contained within. The REC staff developed these materials based on the technology and law that were in place at the time this document was developed. Therefore, advances in technology and/or changes to the law subsequent to that date may not have been incorporated into this material.

NATIONAL LEARNING CONSORTIUM

The National Learning Consortium (NLC) is a virtual and evolving body of knowledge and tools designed to support healthcare providers and health IT professionals working towards the implementation, adoption and meaningful use of certified EHR systems.

The NLC represents the collective EHR implementation experiences and knowledge gained directly from the field of ONC's outreach programs ([REC](#), [Beacon](#), [State HIE](#)) and through the [Health Information Technology Research Center \(HITRC\)](#) Communities of Practice (CoPs).

The following resource is an example of a tool used in the field today that is recommended by "boots-on-the-ground" professionals for use by others who have made the commitment to implement or upgrade to certified EHR systems.

DESCRIPTION

The Clinical Quality Measure (CQM) quick reference guides provide a summary of key information for CQMs and are intended to be shared with clinical staff using an electronic health record (EHR). The first two sections may be distributed as stand-alone references.

The first section, *Quick Facts*, comes from the CQM e-specifications and is intended to provide an overview of the measure. This section provides information on the measure definition, whether the measure is a core, alternate core, or menu set measure, whether it is related to other measures by common data elements, and what data goes into a numerator, denominator, and exclusions and exceptions.

The second section, *Key Clinical Activities* and *Planning Your EHR Documentation*, is intended to be a space to plan EHR documentation. It provides a "to-do list" of clinical and documentation activities for the measure and lists each data element that is required to calculate the numerator, denominator, and exceptions or exclusions. Providers can use this space to assign individuals or roles to tasks in the to-do list.

The third section, *Technical Supplement*, provides clarifications regarding what "counts" toward this measure. First, it provides English "translations" of the numeric SNOMED-CT, HL7, ICD, and CPT codes that may be used in this measure. Second, it includes clarifications on what constitutes a numerator "hit" or a denominator exclusion based on questions that have arisen during technical assistance calls.

To access the official electronic specifications, visit the CMS Electronic Specifications page <https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/QualityMeasures/ElectronicSpecifications.html> and locate the "EP Measure Specifications" zip file, which contains electronic specifications for all 44 Stage 1 Meaningful Use clinical quality measures.

TABLE OF CONTENTS

NQF 0038: Childhood Immunization Status.....	4
Technical Supplement.....	1
Denominator Inclusion Criteria	2
Numerator Inclusion Criteria (Numerator 1)	3
Numerator Inclusion Criteria (Numerator 2)	5
Numerator inclusion criteria (Numerator 3)	5
Numerator Inclusion Criteria (Numerator 4)	7
Numerator Inclusion Criteria (Numerator 5)	8
Numerator Inclusion Criteria (Numerator 6)	9
Numerator Inclusion Criteria (Numerator 7)	10
Numerator Inclusion Criteria (Numerator 8)	11
Numerator Inclusion Criteria (Numerator 9)	12
Numerator inclusion criteria (Numerator 10)	12
Numerator inclusion criteria (Numerator 11 & 12)	13
Exclusion or Exception criteria (Numerator 1)	13
Exclusion or Exception criteria (Numerator 2)	15
Exclusion or Exception criteria (Numerator 3)	15
Exclusion or Exception criteria (Numerator 4)	35
Exclusion or Exception criteria (Numerator 6)	35
Exclusion or Exception criteria (Numerator 7)	36
Exclusion or Exception criteria (Numerator 8)	36
Exclusion or Exception criteria (Numerator 9)	37
Exclusion or Exception criteria (Numerator 10)	37
Exclusion or Exception criteria (Numerator 11 & 12)	38
Types of codes required from your EHR for calculating this clinical quality measure	38

NQF 0038: Childhood Immunization Status

Percentage of children 2 years of age who had four diphtheria, tetanus and acellular pertussis (DTaP); three polio (IPV), one measles, mumps and rubella (MMR); two H influenza type B (HiB); three hepatitis B (Hep B); one chicken pox (VZV); four pneumococcal conjugate (PCV); two hepatitis A (Hep A); two or three rotavirus (RV); and two influenza (flu) vaccines by their second birthday. The measure calculates a rate for each vaccine and two separate combination rates.

Quick Facts	
Type of measure: core, alternate core, or menu?	<ul style="list-style-type: none"> Alternate core measure
Related to other measures?	<ul style="list-style-type: none"> Not related to other Stage 1 MU clinical quality measures
Data required to identify the <u>denominator</u> (total cases eligible to be counted in measure)	<ul style="list-style-type: none"> Age Encounter codes¹
Data required to identify the <u>12 exceptions or exclusions</u>	<ul style="list-style-type: none"> Medication allergy: DTaP1, neomycin², streptomycin², polymyxin², MMR vaccine³, mumps vaccine², measles vaccine², VZV vaccine², influenza vaccine², hepatitis B vaccine², hepatitis A vaccine², rotavirus vaccine², pneumococcal vaccination², HiB², rubella vaccine², IPV² Substance allergy: Baker's yeast substance² Active diagnosis: cancer of lymphoreticular or histiocytic tissue, progressive neurological disorder, HIV disease, multiple myeloma, leukemia, immunodeficiency²
Data required to identify the <u>12 numerators</u> (cases in which the process or outcome being measure occurred)	<ul style="list-style-type: none"> Date of 4 DTaP; 3 IPV; 1 MMR, <u>or</u> 1 measles, 1 mumps, and 1 rubella; 2 HiB; hepatitis B vaccine, VZV vaccine, influenza vaccine, hepatitis A vaccine, rotavirus vaccine² Diagnosis of mumps, rubella, hepatitis A, VZV, hepatitis B²

Note: This document is meant to supplement and not replace the official electronic specifications for the measure. To access the official specifications, visit: <https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/QualityMeasures/ElectronicSpecifications.html>

Key Clinical Activities		Planning Your EHR Documentation	
To-Do List	Why Needed?	Data Elements Needed	Responsible Person or Role
1. Confirm the patient's date of birth	<ul style="list-style-type: none"> Confirms only patients who are 2 years old at any time during the measurement period are counted in the denominator. 	<ul style="list-style-type: none"> Date of birth 	
2. Record date and type of visit	<ul style="list-style-type: none"> Ensures only appropriate visits are captured in the denominator 	<ul style="list-style-type: none"> Date of visit Code for a PCP or Ob/Gyn outpatient encounter⁴ 	

¹ This data element(s) must be documented before or simultaneous to the measurement end date.

² This data element(s) must be documented before the measurement end date

³ This data element(s) must be documented no more than 2 years before the measurement end date

⁴ See Technical Supplement for denominator inclusion details (encounter types): pp. TS-2

Key Clinical Activities		Planning Your EHR Documentation	
To-Do List	Why Needed?	Data Elements Needed	Responsible Person or Role
3. Perform DTaP vaccination series, if not already present.	<ul style="list-style-type: none"> • Captures the vaccination activity in your EHR for numerator 1⁵ 	<ul style="list-style-type: none"> • Dates of DTaP vaccine series (≥4 counts) 	
4. If not present and not given, assess why DTaP vaccines cannot be given.	<ul style="list-style-type: none"> • Ensures that the appropriate patients are identified as exclusions or exceptions (Exclusion 1) 	<ul style="list-style-type: none"> • Document: <ul style="list-style-type: none"> – medication allergy to the DTaP vaccine⁶, or – diagnosis for encephalopathy or progressive neurological disorder⁶ 	
5. Perform IPV vaccination series, if not already present.	<ul style="list-style-type: none"> • Captures the vaccination activity in your EHR for numerator 2 	<ul style="list-style-type: none"> • Dates of IPV vaccine series (≥3 counts) 	
6. If not present and not given, assess why IPV vaccines cannot be given.	<ul style="list-style-type: none"> • Ensures that the appropriate patients are identified as exclusions or exceptions (Exclusion 2) 	<ul style="list-style-type: none"> • Document medication allergy to IPV, neomycin, • Streptomycin, or polymyxin 	
7. Perform MMR vaccination, if not already present.	<ul style="list-style-type: none"> • Captures the vaccination activity in your EHR for numerator 3a 	<ul style="list-style-type: none"> • Date of MMR vaccine (≥1 count) 	
8. If not present and not given, assess why MMR vaccines cannot be given.	<ul style="list-style-type: none"> • Ensures that the appropriate patients are identified as exclusions or exceptions (Exclusion 3a) 	<ul style="list-style-type: none"> • Document: <ul style="list-style-type: none"> – medication allergy to the MMR, mumps, measles, rubella vaccine, or – diagnosis for cancer of lymphoreticular or histiocytic tissue, HIV disease, multiple myeloma, leukemia, or immunodeficiency 	
9. (If MMR not given) Perform mumps, measles and rubella vaccinations, if not	<ul style="list-style-type: none"> • Captures the vaccination activity in your EHR for numerator 3b. 	<ul style="list-style-type: none"> • Date of rubella vaccine (≥1 count) • Date of measles vaccine (≥1 count) • Date of mump vaccine (≥1 count) 	

⁵ See Technical Supplement for numerator inclusion details (all numerators): [pp. TS-3](#)

⁶ See Technical Supplement for exclusion or exception details (all numerators): [pp. TS-13](#)

Key Clinical Activities		Planning Your EHR Documentation	
To-Do List	Why Needed?	Data Elements Needed	Responsible Person or Role
10. If not present and not given, assess why mumps, measles and rubella vaccines cannot be given.	<ul style="list-style-type: none"> Ensures that the appropriate patients are identified as exclusions or exceptions (Exclusion 3b) 	<ul style="list-style-type: none"> Document: <ul style="list-style-type: none"> medication allergy to the MMR, mumps, measles, rubella vaccine, or diagnosis for cancer of lymphoreticular or histiocytic tissue, HIV disease, multiple myeloma, leukemia, or immunodeficiency 	
11. Perform HiB vaccination series, if not present.	<ul style="list-style-type: none"> Captures the vaccination activity in your EHR for numerator 4 	<ul style="list-style-type: none"> Dates of HiB vaccine series (≥ 2 counts) 	
12. If not present and not given, assess why the HiB vaccines cannot be given.	<ul style="list-style-type: none"> Ensures that the appropriate patients are identified as exclusions or exceptions (Exclusion 4) 	<ul style="list-style-type: none"> Document medication allergy to the HiB vaccine 	
13. Check if patient has or had hepatitis B. If	<ul style="list-style-type: none"> Captures the vaccination activity in your EHR for numerator 5. 	<ul style="list-style-type: none"> Dates of hepatitis B vaccine series (≥ 3 counts) [or] Note diagnosis of hepatitis B 	
14. If not present and not given, assess why the Hepatitis B vaccines cannot be given.	<ul style="list-style-type: none"> Ensures that the appropriate patients are identified as exclusions or exceptions (Exclusion 5) 	<ul style="list-style-type: none"> Document: <ul style="list-style-type: none"> Medication allergy to hepatitis B vaccine; or Allergy to Baker's yeast (or its substance) 	
15. Check if patient had VZV in the past. If not, perform VZV vaccination, if not already present.	<ul style="list-style-type: none"> Captures the vaccination activity in your EHR for numerator 6. 	<ul style="list-style-type: none"> Date of VZV vaccine (≥ 1 count) Note diagnosis of VZV 	
16. If not present and not given, assess why the VZV vaccine cannot be given.	<ul style="list-style-type: none"> Ensures that the appropriate patients are identified as exclusions or exceptions (Exclusion 6) 	<ul style="list-style-type: none"> Document: <ul style="list-style-type: none"> medication allergy to the VZV vaccine, or diagnosis for cancer of lymphoreticular or histiocytic tissue, HIV disease, multiple myeloma, leukemia, or immunodeficiency 	

Key Clinical Activities		Planning Your EHR Documentation	
To-Do List	Why Needed?	Data Elements Needed	Responsible Person or Role
17. Perform pneumococcal vaccination series, if not already present.	<ul style="list-style-type: none"> • Captures the vaccination activity in your EHR for numerator 7. 	<ul style="list-style-type: none"> • Dates of pneumococcal vaccine series (≥ 4 counts) 	
18. Check if patient had hepatitis A in the past. If not, perform hepatitis A vaccination series, if not already present.	<ul style="list-style-type: none"> • Captures the vaccination activity in your EHR for numerator 8. 	<ul style="list-style-type: none"> • Dates of hepatitis A vaccine series (≥ 2 counts) • Note diagnosis of hepatitis A 	
19. If not present and not given, assess why the hepatitis A vaccines cannot be given.	<ul style="list-style-type: none"> • Ensures that the appropriate patients are identified as exclusions or exceptions (Exclusion 8) 	<ul style="list-style-type: none"> • Document medication allergy to the hepatitis A vaccine 	
20. Perform rotavirus vaccination series, if not already present.	<ul style="list-style-type: none"> • Captures the vaccination activity in your EHR for numerator 9. 	<ul style="list-style-type: none"> • Dates of rotavirus vaccine series (≥ 2 counts) 	
21. If not present and not given, assess why the rotavirus vaccines cannot be given.	<ul style="list-style-type: none"> • Ensures that the appropriate patients are identified as exclusions or exceptions (Exclusion 9) 	<ul style="list-style-type: none"> • Document medication allergy to the rotavirus vaccine 	
22. Perform influenza vaccinations, if not already present.	<ul style="list-style-type: none"> • Captures the vaccination activity in your EHR for numerator 10. 	<ul style="list-style-type: none"> • Dates of influenza vaccines (≥ 2 counts) 	
23. If not present and not given, assess why the influenza vaccines cannot be given.	<ul style="list-style-type: none"> • Ensures that the appropriate patients are identified as exclusions or exceptions (Exclusion 10) 	<ul style="list-style-type: none"> • Document: <ul style="list-style-type: none"> – medication allergy to the influenza vaccine, or – diagnosis for cancer of lymphoreticular or histiocytic tissue, HIV disease, multiple myeloma, leukemia, or immunodeficiency 	
24. See Numerators 1 through 6.	<ul style="list-style-type: none"> • Captures the vaccination activity in your EHR for numerator 11. 	<ul style="list-style-type: none"> • Dates from Numerators 1 through 6 	
25. See Denominator Exclusions 1 through 6.	<ul style="list-style-type: none"> • Ensures that the appropriate patients are identified as exclusions or exceptions (Exclusion 11) 	<ul style="list-style-type: none"> • Documentation from Denominator Exception or Exclusion 1 through 6 	

Key Clinical Activities		Planning Your EHR Documentation	
To-Do List	Why Needed?	Data Elements Needed	Responsible Person or Role
26. See Numerators 1 through 7.	<ul style="list-style-type: none"> Captures the vaccination activity in your EHR for numerator 12. 	<ul style="list-style-type: none"> Dates from Numerators 1 through 7 	
27. See Denominator Exclusions 1 through 7.	<ul style="list-style-type: none"> Ensures that the appropriate patients are identified as exclusions or exceptions (Exclusion 12) 	<ul style="list-style-type: none"> Documentation from Denominator Exception or Exclusion 1 through 7 	

Technical Supplement

The following pages list the technical definitions of the codes that could be included in the calculation of this measure. Use these lists as needed to confirm that your clinical documentation includes item(s) that are on this list, where appropriate, to ensure accurate calculation of your quality measure numerator and denominator.

DENOMINATOR INCLUSION CRITERIA

What constitutes a visit or encounter? (ICD-9-CM codes)

- Postpartum care and examination
- Encounter for contraceptive management
- Procreative Management
- Outcome of delivery
- Encounter for antenatal screening of mother
- Presence of contraceptive device
- Multiparity
- Illegitimacy or illegitimate pregnancy
- Other unwanted pregnancy
- High risk sexual behavior
- Gynecological examination
- Pregnancy examination or test
- General medical examination
- Other medical examination for administrative purposes
- Health examination of defined subpopulations.
- Health examination in population surveys
- Other specified general medical examinations
- Unspecified general medical examination

What constitutes a visit or encounter? (ICD-10-CM codes)

- | | |
|---|--------------|
| • Routine child health examination | Z00.1 |
| • Unknown description | Z00.10 |
| • Newborn health examination | Z00.11 |
| • Examination for period of rapid growth in childhood | Z00.2 |
| • Examination for adolescent development rate | Z00.3 |
| • Examination for period of delayed growth in childhood | Z00.7-Z00.71 |
| • Other general examinations | Z00.8 |

What constitutes a visit or encounter? (CPT Codes)

- Office or other outpatient visit for the evaluation and management of a new patient, which requires these 3 key components: a history, an examination, & medical decision making.
- Office or other outpatient visit for the evaluation and management of an established patient that may not require the presence of a physician.
- Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: a history, an examination, and medical decision making.
- Observation care discharge day management (This code is to be utilized by the physician to report all services provided to a patient on discharge from "observation status" if the discharge is on other than the initial date of "observation status." To report services to a patient designated as "observation status" or "inpatient status" and discharged on the same date, use the codes from Observation or Inpatient Care Services [including Admission and Discharge Services, 99234-99236 as appropriate.]

What constitutes a visit or encounter? (CPT Codes)

- Initial observation care, per day, for the evaluation and management of a patient which requires these 3 key components: a history, an examination, and medical decision making.
- Office consultation for a new or established patient, which requires these 3 key components: a history, an examination, and medical decision making.
- Home visit for the evaluation and management of a new patient, which requires these 3 key components: A history, an examination, and medical decision making.
- Home visit for the evaluation and management of an established patient, which requires 2 of these 3 key components: a history, an examination, and medical decision making.
- Initial comprehensive preventive medicine evaluation and management of an individual, including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient
- Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient.
- Preventive medicine counseling and/or risk factor reduction intervention(s) provided to an individual (distinct from evaluation and management)
- Preventive medicine counseling and/or risk factor reduction intervention(s) provided to individuals in a group setting (distinct from evaluation and management)
- Administration and interpretation of health risk assessment instrument (e.g., health hazard appraisal)
- Unlisted preventive medicine service
- Work related or medical disability examination by treating or other physician that includes: Completion of a medical history commensurate with the patient's condition, performance of an examination commensurate with the patient's condition, formulation of a diagnosis, assessment of capabilities and stability, and calculation of impairment, development of future medical treatment plan, and completion of necessary documentation/certificates and report.

NUMERATOR INCLUSION CRITERIA (NUMERATOR 1)

What constitutes a DTaP Vaccination (Numerator 1)? (RXNorm)

- Diphtheria Toxoid Vaccine 4 UNT/ML / Tetanus Toxoid Vaccine 4 UNT/ML Injectable Suspension
- Hoplosathe formosa
- Acellular Pertussis Vaccine 0.0936 MG/ML / Diphtheria Toxoid Vaccine 13.2 UNT/ML / Tetanus Toxoid Vaccine 10 UNT/ML Injectable Suspension
- Acellular Pertussis Vaccine 0.08 MG/ML / Diphtheria Toxoid Vaccine 30 UNT/ML / Tetanus Toxoid Vaccine 12 UNT/ML Injectable Suspension
- Acellular Pertussis Vaccine 8 UNT/ML / Diphtheria Toxoid Vaccine 13.4 UNT/ML / Tetanus Toxoid Vaccine 10 UNT/ML Injectable Suspension
- Acellular Pertussis Vaccine 0.936 UNT/ML / Diphtheria Toxoid Vaccine 13.4 UNT/ML / Tetanus Toxoid Vaccine 10 UNT/ML Injectable Suspension
- 0.5 ML Acellular Pertussis Vaccine 0.936 MG/ML / Diphtheria Toxoid Vaccine 13.4 UNT/ML / Tetanus Toxoid Vaccine 10 UNT/ML Injectable Suspension
- Acellular Pertussis Vaccine 96 UNT/ML / Diphtheria Toxoid Vaccine 30 UNT/ML / Haemophilus influenzae b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 68 UNT/ML / Inactivated Polioviruses Type 1, Mahoney strain vaccine 80 UNT/ML / Inactivated Polioviruses Type 2, MEF-1 strain vaccine 16 UNT/ML / Inactivated Polioviruses Type 3, Saukett strain vaccine 64 UNT/ML / Tetanus Toxoid Vaccine 20 UNT/ML Injectable Suspension
- Diphtheria Toxoid Vaccine 13.4 UNT/ML / Tetanus Toxoid Vaccine 10 UNT/ML Injectable Suspension

What constitutes a DTaP Vaccination (Numerator 1)? (RXNorm)

- Acellular Pertussis Vaccine 0.037 MG/ML / Diphtheria Toxoid Vaccine 5 UNT/ML / Tetanus Toxoid Vaccine 10 UNT/ML Injectable Suspension
- 0.5 ML Acellular Pertussis Vaccine 0.037 MG/ML / Diphtheria Toxoid Vaccine 5 UNT/ML / Tetanus Toxoid Vaccine 10 UNT/ML Prefilled Syringe
- Acellular Pertussis Vaccine 8 UNT/ML / Diphtheria Toxoid Vaccine 25 UNT/ML / Tetanus Toxoid Vaccine 10 UNT/ML Injectable Suspension
- Hymenoptera sp. BOLD:AAB5730
- Acellular Pertussis Vaccine 0.116 MG/ML / Diphtheria Toxoid Vaccine 50 UNT/ML / Tetanus Toxoid Vaccine 20 UNT/ML Injectable Suspension
- Acellular Pertussis Vaccine 0.116 MG/ML / Diphtheria Toxoid Vaccine 50 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML
- 0.5 ML Acellular Pertussis Vaccine 0.116 MG/ML / Diphtheria Toxoid Vaccine 50 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML / Poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / Poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / Poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / Tetanus Toxoid Vaccine 20 UNT/ML Prefilled Syringe
- Acellular Pertussis Vaccine 0.08 MG/ML / Diphtheria Toxoid Vaccine 18 UNT/ML / Tetanus Toxoid Vaccine 10 UNT/ML Injectable Suspension
- Acellular Pertussis Vaccine 0.116 MG/ML / Diphtheria Toxoid Vaccine 50 UNT/ML / Poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / Poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / Poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / Tetanus Toxoid Vaccine 20 UNT/ML Injectable Suspension
- 0.5 ML Acellular Pertussis Vaccine 0.116 MG/ML / Diphtheria Toxoid Vaccine 50 UNT/ML / Poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / Poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / Poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / Tetanus Toxoid Vaccine 20 UNT/ML Prefilled Syringe
- Acellular Pertussis Vaccine 0.031 MG/ML / Diphtheria Toxoid Vaccine 4 UNT/ML / Tetanus Toxoid Vaccine 10 UNT/ML Injectable Suspension
- Acellular Pertussis Vaccine 0.046 MG/ML / Diphtheria Toxoid Vaccine 30 UNT/ML / Tetanus Toxoid Vaccine 10 UNT/ML Injectable Suspension

What constitutes a DTaP Vaccination (Numerator 1)? (CPT Codes)

- Diphtheria, tetanus toxoids, acellular pertussis vaccine, haemophilus influenza Type B, and poliovirus vaccine, inactivated (DTaP - Hib - IPV), for intramuscular use
- Diphtheria, tetanus toxoids, and acellular pertussis vaccine (DTaP), when administered to individuals younger than 7 years, for intramuscular use
- Diphtheria, tetanus toxoids, and acellular pertussis vaccine and Hemophilus influenza B vaccine (DtaP-Hib), for intramuscular use
- Diphtheria, tetanus toxoids, acellular pertussis vaccine, Hepatitis B, and poliovirus vaccine, inactivated (DtaP-HepB-IPV), for intramuscular use

What constitutes a DTaP Vaccination (Numerator 1)? (CVX Codes)

- DTaP –Hep B-IPV (Pediarix)
- DTaP-HiB-IPV (Pentacel)
- DTaP (pediatric)
- 50DTaP-HiB (Trihibit)

NUMERATOR INCLUSION CRITERIA (NUMERATOR 2)

What constitutes an IPV Vaccination (Numerator 2)? (RXNorm)

- Poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / Poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / Poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML Injectable Solution
- 0.5 ML Poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / Poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / Poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML Prefilled Syringe

What constitutes an IPV Vaccination (Numerator 2)? (CPT Codes)

- Poliovirus vaccine, inactivated (IPV), for subcutaneous or intramuscular use
- Diphtheria, tetanus toxoids, acellular pertussis vaccine, Hepatitis B, and poliovirus vaccine, inactivated (DtaP-HepB-IPV), for intramuscular use

What constitutes an IPV Vaccination (Numerator 2)? (CVX Codes)

- IPV (Polio)
- DTaP-HiB-IPV (Pentacel)

NUMERATOR INCLUSION CRITERIA (NUMERATOR 3)

What constitutes a measles, mumps, and/or rubella vaccination (Numerators 3a & 3b)? (RXNorm)

- Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML Injectable Solution
- Mumps Virus Vaccine Live, Jeryl Lynn Strain 40000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML Injectable Solution
- Mumps Virus Vaccine Live, Jeryl Lynn Strain 40000 UNT/ML Injectable Solution
- Measles Virus Vaccine, Live Attenuated 2000 UNT/ML Injectable Solution
- Measles Vaccine 2000 UNT/ML Injectable Solution
- Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 UNT/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 25000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML Injectable Solution
- Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 UNT/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 40000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML / Varicella Virus Vaccine Live (Oka-Merck) strain 20000 UNT/ML Injectable Solution
- ProQuad, measles, mumps, rubella, and varicella virus vaccine, live, injectable solution
- MMR II, measles, mumps, and rubella virus, live, injectable solution

What constitutes a measles, mumps, and/or rubella vaccination (Numerators 3a & 3b)? (CPT Codes)

- Measles virus vaccine, live, for subcutaneous use
- Measles, mumps and rubella virus vaccine (MMR), live, for subcutaneous use
- Rubella and mumps virus vaccine, live, for subcutaneous use
- Mumps virus vaccine, live, for subcutaneous or jet injection use
- Rubella virus vaccine, live, for subcutaneous use

What constitutes a measles, mumps, and/or rubella vaccination (Numerators 3a & 3b)? (CVX Codes)

- Measles
- MMR
- MMRV (ProQuad)

What constitutes a measles, mumps, and/or rubella vaccination (Numerators 3a & 3b)? (CVX Codes)

- Mumps
- Rubella

What constitutes a measles, mumps, and/or rubella vaccination (Numerators 3a & 3b)? (ICD-10-CM)

• Measles	B05
• Mumps	B26
• Mumps Orchitis	B26.0
• Mumps Meningitis	B26.1
• Mumps Encephalitis	B26.2
• Mumps Pancreatitis	B26.3
• Mumps with other complications	B26.8
• Mumps hepatitis	B26.81
• Mumps myocarditis	B26.82
• Mumps nephritis	B26.83
• Mumps polyneuropathy	B26.84
• Mumps arthritis	B26.85
• Other mumps complications	B26.89
• Mumps without complication	B26.9
• Rubella	B06
• Rubella without complication	B06.9

What constitutes a measles, mumps, and/or rubella vaccination (Numerators 3a & 3b)? (ICD-9-CM Codes)

• Measles	055
• Rubella	056

What constitutes a measles, mumps, and/or rubella vaccination (Numerators 3a & 3b)? (SNOMED-CT)

- Measles without complication
- Measles without mention of complication
- Measles complicated by meningitis
- Measles with intestinal complications
- Subacute Sclerosing Panencephalitis
- Measles pneumonia
- GIP - Giant cell interstitial pneumonitis
- Atypical measles
- Modified measles
- Measles keratitis
- Measles with complication
- Measles of the central nervous system
- Measles keratoconjunctivitis
- Measles myocarditis
- Mumps pancreatitis

What constitutes a measles, mumps, and/or rubella vaccination (Numerators 3a & 3b)? (SNOMED-CT)

- Mumps without complication
- Mumps nephritis
- Mumps acute sialadenitis
- Mumps epididymo-orchitis
- Mastitis of mumps
- Mumps
- Mumps submandibular sialadenitis
- Mumps sublingual sialadenitis
- Mumps polyneuropathy
- Mumps encephalitis
- Mumps meningoencephalitis
- Mumps meningitis44201003
- Mumps myocarditis
- Mumps thyroiditis
- Mumps with complication
- Mumps oophoritis
- Mumps orchitis
- Mumps arthritis
- Rubella encephalomyelitis
- Rubella without complication
- Rubella infection of central nervous system
- Rubella meningoencephalitis
- Congenital Rubella Syndrome
- Rubella with neurological complication
- Rubella deafness
- Rubella arthritis
- Endocochlear rubella
- Hemorrhagic rubella
- Rubella cataract
- Rubella in mother complicating pregnancy, childbirth AND/OR puerperium
- Rubella in pregnancy
- Progressive congenital rubella encephalomyelitis
- Rubella
- Congenital rubella pneumonitis
- Rubella myocarditis
- Expanded rubella syndrome
- Rubella with complication

NUMERATOR INCLUSION CRITERIA (NUMERATOR 4)

What constitutes an HiB vaccination (Numerator 4)? (RXNorm)

- Haemophilus capsular oligosaccharide 0.02 MG/ML / Tetanus Toxoid Vaccine 0.048 MG/ML Injectable Solution

What constitutes an HiB vaccination (Numerator 4)? (RXNorm)

- Haemophilus influenzae b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.068 MG/ML Injectable Solution
- 0.5 ML Haemophilus influenzae b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.068 MG/ML Injectable Solution
- Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine 0.265 MG/ML / Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension
- Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine 0.265 MG/ML Injectable Suspension
- Haemophilus b polysaccharide vaccine 0.02 MG/ML

What constitutes an HiB vaccination (Numerator 4) (CPT Codes)

- Hemophilus influenza b vaccine (Hib), HbOC conjugate (4 dose schedule), for intramuscular use
- Hemophilus influenza b vaccine (Hib), PRP-D conjugate, for booster use only, intramuscular use
- Hemophilus influenza b vaccine (Hib), PRP-OMP conjugate (3 dose schedule), for intramuscular use
- Hemophilus influenza b vaccine (Hib), PRP-T conjugate (4 dose schedule), for intramuscular use
- Diphtheria, tetanus toxoids, and acellular pertussis vaccine and Hemophilus influenza B vaccine (DtaP-Hib), for intramuscular use

What constitutes an HiB vaccination (Numerator 4) (CVX Codes)

- DTaP-HiB-IPV (Pentacel)
- HiB-ProHIBIT (PRP-D)
- HiB-HiBTITER (HbOC)
- HiB (PRP-T) (ActHiB/Hiberix)
- Hib (PedaxHib) (3-dose, PRP-OMP)
- DTaP-HiB (Trihibit)
- HiB-HepB (Comvax)

NUMERATOR INCLUSION CRITERIA (NUMERATOR 5)

What constitutes a Hepatitis B vaccination (Numerator 5) (RxNorm)

- Hepatitis B Vaccine 0.01 MG/ML Injectable Suspension
- Hepatitis B Vaccine 0.02 MG/ML Injectable Suspension
- Hepatitis B Vaccine 0.04 MG/ML Injectable Suspension
- Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine 0.265 MG/ML / Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension
- Hepatitis A Vaccine, Inactivated 720 UNT/ML / Hepatitis B Vaccine 0.02 MG/ML Injectable Suspension
- 0.5 ML Hepatitis B Vaccine 0.02 MG/ML Prefilled Syringe

What constitutes a Hepatitis B vaccination (Numerator 5)? (CPT Codes)

- Diphtheria, tetanus toxoids, acellular pertussis vaccine, Hepatitis B, and poliovirus vaccine, inactivated (DtaP-HepB-IPV), for intramuscular use
- Hepatitis B vaccine, dialysis or immunosuppressed patient dosage (3 dose schedule), for intramuscular use
- Hepatitis B vaccine, pediatric/adolescent dosage (3 dose schedule), for intramuscular use

What constitutes a Hepatitis B vaccination (Numerator 5)? (CPT Codes)

- Hepatitis B vaccine, dialysis or immunosuppressed patient dosage (4 dose schedule), for intramuscular use
- Hepatitis B and Hemophilus influenza b vaccine (HepB-Hib), for intramuscular use

What constitutes a Hepatitis B vaccination (Numerator 5)? (CVX Codes)

- Hepatitis B (pediatric or adolescent)
- DTaP-Hep B-IPV (Pediarix)
- Hepatitis B (dialysis)
- HiB-Hepatitis B (Comvax)

What constitutes resolved Hepatitis B (Numerator 5)? (SNOMED-CT)

- Chronic aggressive type B viral hepatitis
- Viral hepatitis B without hepatic coma
- Acute fulminating type B viral hepatitis
- Viral hepatitis B with coma
- Acute hepatitis B with delta agent (coinfection) with hepatic coma
- Acute hepatitis B with delta-agent (coinfection) without hepatic coma
- Chronic viral hepatitis B without delta-agent
- Acute hepatitis B with hepatitis D
- Chronic viral hepatitis B with hepatitis D
- Viral hepatitis B with hepatic coma
- Relapsing type B viral hepatitis
- Viral hepatitis
- Chronic persistent type B viral hepatitis
- Acute hepatitis B with hepatic coma
- Chronic hepatitis B with hepatic coma
- Hepatitis B with hepatitis D superinfection
- Hepatitis B associated with Human immunodeficiency virus infection
- Hepatitis B and hepatitis C
- Chronic active type B viral hepatitis
- Anicteric type B viral hepatitis
- Congenital viral hepatitis B infection
- Hepatitis B, Chronic
- Hepatitis B
- Acute type B viral hepatitis

NUMERATOR INCLUSION CRITERIA (NUMERATOR 6)

What constitutes a VZV vaccination (Numerator 6)? (RxNorm)

- Varicella zoster vaccine, live (Oka/Merck) 19,400 UNT per 0.65ML injectable suspension
- Zostavax 29800 UNT/ML injectable suspension

What constitutes a VZV vaccination (Numerator 6)? (CPT)

- Measles, mumps, rubella, and varicella vaccine (MMRV), live, for subcutaneous use
- Varicella virus vaccine, live, for subcutaneous use

What constitutes a VZV vaccination (Numerator 6)? (CVX)

- Varicella (Varivax)
- MMRV (ProQuad)

What constitutes resolved VZV (Numerator 6)? (ICD-9)

- Chickenpox
- Herpes Zoster

NUMERATOR INCLUSION CRITERIA (NUMERATOR 7)

What constitutes a pneumococcal vaccination (Numerator 7)? (RxNorm)

- Pneumococcal capsular polysaccharide type 1 vaccine 0.05 MG/ML
- Pneumococcal capsular polysaccharide type 10A vaccine 0.05 MG/ML
- Pneumococcal capsular polysaccharide type 11A vaccine 0.05 MG/ML
- Pneumococcal capsular polysaccharide type 12F vaccine 0.05 MG/ML
- Pneumococcal capsular polysaccharide type 14 vaccine 0.05 MG/ML
- Pneumococcal capsular polysaccharide type 15B vaccine 0.05 MG/ML
- Pneumococcal capsular polysaccharide type 17F vaccine 0.05 MG/ML
- Pneumococcal capsular polysaccharide type 18C vaccine 0.05 MG/ML
- Pneumococcal capsular polysaccharide type 19A vaccine 0.05 MG/ML
- Pneumococcal capsular polysaccharide type 19F vaccine 0.05 MG/ML
- Pneumococcal capsular polysaccharide type 2 vaccine 0.05 MG/ML
- Pneumococcal capsular polysaccharide type 20 vaccine 0.05 MG/ML
- Pneumococcal capsular polysaccharide type 22F vaccine 0.05 MG/ML
- Pneumococcal capsular polysaccharide type 23F vaccine 0.05 MG/ML
- Pneumococcal capsular polysaccharide type 3 vaccine 0.05 MG/ML
- Pneumococcal capsular polysaccharide type 33F vaccine 0.05 MG/ML
- Pneumococcal capsular polysaccharide type 4 vaccine 0.05 MG/ML
- Pneumococcal capsular polysaccharide type 5 vaccine 0.05 MG/ML
- Pneumococcal capsular polysaccharide type 6B vaccine 0.05 MG/ML
- Pneumococcal capsular polysaccharide type 7F vaccine 0.05 MG/ML
- Pneumococcal capsular polysaccharide type 8 vaccine 0.05 MG/ML
- Pneumococcal capsular polysaccharide type 9N vaccine 0.05 MG/ML
- Pneumococcal capsular polysaccharide type 9V vaccine 0.05 MG/ML

What constitutes a pneumococcal vaccination (Numerator 7)? (RxNorm)

- Pneu. capsular polysaccharide type 1 vacc. 0.05 mg/mL /Pneu. capsular polysaccharide type 10A vacc. 0.05 mg/mL /Pneu. capsular polysaccharide type 11A vacc. 0.05 mg/mL /Pneu. capsular polysaccharide type 12F vacc. 0.05 mg/mL /Pneu. capsular polysaccharide type 14 vacc. 0.05 mg/mL /Pneu. capsular polysaccharide type 15B vacc. 0.05 mg/mL /Pneu. capsular polysaccharide type 17F vacc. 0.05 mg/mL /Pneu. capsular polysaccharide type 18C vacc. 0.05 mg/mL /Pneu. capsular polysaccharide type 19A vacc. 0.05 mg/mL /Pneu. capsular polysaccharide type 19F vacc. 0.05 mg/mL /Pneu. capsular polysaccharide type 2 vacc. 0.05 mg/mL /Pneu. capsular polysaccharide type 20 vacc. 0.05 mg/mL /Pneu. capsular polysaccharide type 22F vacc. 0.05 mg/mL /Pneu. capsular polysaccharide type 23F vacc. 0.05 mg/mL /Pneu. capsular polysaccharide type 3 vacc. 0.05 mg/mL /Pneu. capsular polysaccharide type 33F vacc. 0.05 mg/mL /Pneu. capsular polysaccharide type 4 vacc. 0.05 mg/mL /Pneu. capsular polysaccharide type 5 vacc. 0.05 mg/mL /Pneu. capsular polysaccharide type 6B vacc. 0.05 mg/mL /Pneu. capsular polysaccharide type 7F vacc. 0.05 mg/mL /Pneu. capsular polysaccharide type 8 vacc. 0.05 mg/mL /Pneu. capsular polysaccharide type 9N vacc. 0.05 mg/mL /Pneu. capsular polysaccharide type 9V vacc. 0.05 mg/mL Injectable Solution

What constitutes a pneumococcal vaccination (Numerator 7)? (CPT)

- Pneumococcal conjugate vaccine, 7 valent, for intramuscular use
- Pneumococcal conjugate vaccine, 13 valent, for intramuscular use

What constitutes a pneumococcal vaccination (Numerator 7)? (CVX)

- Pneumococcal Conjugate (PCV7)(Prevnar)
- Pneumococcal Conjugate (PCV13)(Prevnar13)

NUMERATOR INCLUSION CRITERIA (NUMERATOR 8)

What constitutes a Hepatitis A vaccination (Numerator 8)? (RxNorm)

- Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Injectable Suspension
- 1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe
- 0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe
- Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension
- 1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe

What constitutes a Hepatitis A vaccination (Numerator 8)? (CPT)

- Hepatitis A vaccine, pediatric/adolescent dosage-2 dose schedule, for intramuscular use

What constitutes a Hepatitis A vaccination (Numerator 8)? (CVX)

- Hepatitis A (pediatric or adolescent)

What constitutes resolved Hepatitis A (Numerator 8)? (ICD-9-CM)

- Viral Hepatitis A with hepatic coma
- Viral hepatitis without mention of hepatic coma

What constitutes resolved Hepatitis A (Numerator 8)? (ICD-10-CM)

- Acute hepatitis A

What constitutes resolved Hepatitis A (Numerator 8)? (ICD-10-CM)

- Hepatitis A with hepatic coma
- Hepatitis A without hepatic coma

What constitutes resolved Hepatitis A (Numerator 8)? (SNOMED-CT)

- Viral hepatitis A without hepatic coma
- Viral hepatitis A with hepatic coma
- Viral hepatitis A with coma
- Acute fulminating type A viral hepatitis
- Congenital hepatitis A infection
- Acute type A viral hepatitis
- Hepatitis A
- Viral hepatitis A without hepatic coma, without hepatitis delta
- Relapsing type A viral hepatitis
- Anicteric type A viral hepatitis

NUMERATOR INCLUSION CRITERIA (NUMERATOR 9)

What constitutes a rotavirus vaccination (Numerator 9)? (RxNorm)

- Human-Bovine Reassortant Rotavirus Strain G1 Vaccine 1100000 UNT/ML / Human-Bovine Reassortant Rotavirus Strain G2 Vaccine 1400000 UNT/ML / Human-Bovine Reassortant Rotavirus Strain G3 Vaccine 1100000 UNT/ML / Human-Bovine Reassortant Rotavirus Strain G4 Vaccine 1000000 UNT/ML / Human-Bovine Reassortant Rotavirus Strain P1A[8] Vaccine 1150000 UNT/ML Oral Suspension
- Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 1000000 UNT/ML Oral Suspension

What constitutes a rotavirus vaccination (Numerator 9)? (CPT)

- Rotavirus vaccine, tetravalent, live, oral
- Rotavirus vaccine, human, attenuated, 2 dose schedule, live, for oral use

What constitutes a rotavirus vaccination (Numerator 9)? (CVX)

- Rotavirus Monvalent (2-dose, Rotarix, RV1)
- Rotavirus Pentavalent (3-dose, Rotateq, RV5)

NUMERATOR INCLUSION CRITERIA (NUMERATOR 10)

What constitutes an influenza vaccination (Numerator 10)? (RxNorm)

- Influenza Virus Vaccine, Inactivated A-Brisbane-10-2007 (H3N2)-like virus (A-Uruguay-716-2007 NYMC X-175C) strain 0.03 MG/ML / Influenza Virus Vaccine, Inactivated A-Brisbane-59-2007 (H1N1)-like virus (A-Brisbane-59-2007 IVR-148) strain 0.03 MG/ML / Influenza Virus Vaccine, Inactivated, B-Florida-4-2006-like virus (B-Florida-4-2006) strain 0.03 MG/ML Injectable Suspension
- 0.5 ML Influenza Virus Vaccine, Inactivated A-Brisbane-10-2007 (H3N2)-like virus (A-Uruguay-716-2007 NYMC X-175C) strain 0.03 MG/ML / Influenza Virus Vaccine, Inactivated A-Brisbane-59-2007 (H1N1)-like virus (A-Brisbane-59-2007 IVR-148) strain 0.03 MG/ML / Influenza Virus Vaccine, Inactivated, B-Florida-4-2006-like virus (B-Florida-4-2006) strain 0.03 MG/ML Prefilled Syringe

What constitutes an influenza vaccination (Numerator 10)? (RxNorm)

- 0.25 ML Influenza Virus Vaccine, Inactivated A-Brisbane-59-2007 (H1N1) strain 0.03 MG/ML / Influenza Virus Vaccine, Inactivated A-Uruguay-716-2007 (H3N2) (A-Brisbane-10-2007-like) strain 0.03 MG/ML / Influenza Virus Vaccine, Inactivated B-Florida-4-2006 strain 0.03 MG/ML Prefilled Syringe
- 0.5 ML Influenza Virus Vaccine, Inactivated A-Brisbane-59-2007, IVR-148 (H1N1) strain 0.03 MG/ML / Influenza Virus Vaccine, Inactivated A-Uruguay-716-2007, NYMC X-175C (H3N2) strain 0.03 MG/ML / Influenza Virus Vaccine, Inactivated B-Brisbane-60-2008 strain 0.03 MG/ML Prefilled Syringe
- 0.25 ML Influenza Virus Vaccine, Inactivated A-Brisbane-59-2007, IVR-148 (H1N1) strain 0.03 MG/ML / Influenza Virus Vaccine, Inactivated A-Uruguay-716-2007, NYMC X-175C (H3N2) strain 0.03 MG/ML / Influenza Virus Vaccine, Inactivated B-Brisbane-60-2008 strain 0.03 MG/ML Prefilled Syringe
- 0.25 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML Prefilled Syringe
- 0.5 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML Prefilled Syringe
- 0.2 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 158000000 UNT/ML Nasal Spray

What constitutes an influenza vaccination (Numerator 10)? (CPT)

- Influenza virus vaccine, split virus, preservative free, when administered to children 6-35 months of age, for intramuscular use
- Influenza virus vaccine, split virus, when administered to children 6-35 months of age, for intramuscular use
- Influenza virus vaccine, derived from cell cultures, subunit, preservative and antibiotic free, for intramuscular use
- Influenza virus vaccine, split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use

What constitutes an influenza vaccination (Numerator 10)? (CVX)

- Influenza High Dose (Fluzone)
- Influenza TIV

NUMERATOR INCLUSION CRITERIA (NUMERATOR 11 & 12)

For numerator 11, see inclusion criteria for numerators 1-6

For numerator 12, see inclusion criteria for numerators 1-7

EXCLUSION OR EXCEPTION CRITERIA (NUMERATOR 1)

What constitutes an exclusion for DTaP Vaccination (Numerator 1)? (RXNorm)

- Diphtheria Toxoid Vaccine 30 UNT/ML / Tetanus Toxoid Vaccine 20 UNT/ML Injectable Suspension
- Diphtheria Toxoid Vaccine 4 UNT/ML / Tetanus Toxoid Vaccine 20 UNT/ML Injectable Suspension
- Diphtheria Toxoid Vaccine 4 UNT/ML / Tetanus Toxoid Vaccine 4 UNT/ML Injectable Suspension
- Diphtheria Toxoid Vaccine 0.036 MG/ML / Haemophilus capsular oligosaccharide 0.05 MG/ML Injectable Solution
- Hoplosathe formosa
- Acellular Pertussis Vaccine 0.0936 MG/ML / Diphtheria Toxoid Vaccine 13.2 UNT/ML / Tetanus Toxoid Vaccine 10 UNT/ML Injectable Suspension
- Diphtheria Toxoid Vaccine 13.4 UNT/ML / Tetanus Toxoid Vaccine 10 UNT/ML Injectable Solution
- Acellular Pertussis Vaccine 0.08 MG/ML / Diphtheria Toxoid Vaccine 30 UNT/ML / Tetanus Toxoid Vaccine 12 UNT/ML Injectable Suspension
- Acellular Pertussis Vaccine 8 UNT/ML / Diphtheria Toxoid Vaccine 13.4 UNT/ML / Tetanus Toxoid Vaccine 10 UNT/ML Injectable Suspension

What constitutes an exclusion for DTaP Vaccination (Numerator 1)? (RXNorm)

- Diphtheria Toxoid Vaccine 0.05 MG/ML / Haemophilus capsular oligosaccharide 0.02 MG/ML Injectable Suspension
- Acellular Pertussis Vaccine 0.936 UNT/ML / Diphtheria Toxoid Vaccine 13.4 UNT/ML / Tetanus Toxoid Vaccine 10 UNT/ML Injectable Suspension
- 0.5 ML Acellular Pertussis Vaccine 0.936 MG/ML / Diphtheria Toxoid Vaccine 13.4 UNT/ML / Tetanus Toxoid Vaccine 10 UNT/ML Injectable Suspension
- Diphtheria Toxoid Vaccine 13.2 UNT/ML / Tetanus Toxoid Vaccine 10 UNT/ML Injectable Suspension
- Acellular Pertussis Vaccine 96 UNT/ML / Diphtheria Toxoid Vaccine 30 UNT/ML / Haemophilus influenzae b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 68 UNT/ML / Inactivated Polioviruses Type 1, Mahoney strain vaccine 80 UNT/ML / Inactivated Polioviruses Type 2, MEF-1 strain vaccine 16 UNT/ML / Inactivated Polioviruses Type 3, Saukett strain vaccine 64 UNT/ML / Tetanus Toxoid Vaccine 20 UNT/ML Injectable Suspension
- Diphtheria Toxoid Vaccine 13.4 UNT/ML / Tetanus Toxoid Vaccine 10 UNT/ML Injectable Suspension
- Acellular Pertussis Vaccine 0.037 MG/ML / Diphtheria Toxoid Vaccine 5 UNT/ML / Tetanus Toxoid Vaccine 10 UNT/ML Injectable Suspension
- 0.5 ML Acellular Pertussis Vaccine 0.037 MG/ML / Diphtheria Toxoid Vaccine 5 UNT/ML / Tetanus Toxoid Vaccine 10 UNT/ML Prefilled Syringe
- Diphtheria Toxoid Vaccine 4 UNT/ML / Tetanus Toxoid Vaccine 10 UNT/ML Injectable Suspension
- Acellular Pertussis Vaccine 8 UNT/ML / Diphtheria Toxoid Vaccine 25 UNT/ML / Tetanus Toxoid Vaccine 10 UNT/ML Injectable Suspension
- Hymenoptera sp. BOLD:AAB5730
- Acellular Pertussis Vaccine 0.116 MG/ML / Diphtheria Toxoid Vaccine 50 UNT/ML / Tetanus Toxoid Vaccine 20 UNT/ML Injectable Suspension
- Acellular Pertussis Vaccine 0.116 MG/ML / Diphtheria Toxoid Vaccine 50 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML
- 0.5 ML Acellular Pertussis Vaccine 0.116 MG/ML / Diphtheria Toxoid Vaccine 50 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML / Poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / Poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / Poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / Tetanus Toxoid Vaccine 20 UNT/ML Prefilled Syringe
- Acellular Pertussis Vaccine 0.08 MG/ML / Diphtheria Toxoid Vaccine 18 UNT/ML / Tetanus Toxoid Vaccine 10 UNT/ML Injectable Suspension
- Acellular Pertussis Vaccine 0.116 MG/ML / Diphtheria Toxoid Vaccine 50 UNT/ML / Poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / Poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / Poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / Tetanus Toxoid Vaccine 20 UNT/ML Injectable Suspension
- 0.5 ML Acellular Pertussis Vaccine 0.116 MG/ML / Diphtheria Toxoid Vaccine 50 UNT/ML / Poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / Poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / Poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / Tetanus Toxoid Vaccine 20 UNT/ML Prefilled Syringe
- Acellular Pertussis Vaccine 0.031 MG/ML / Diphtheria Toxoid Vaccine 4 UNT/ML / Tetanus Toxoid Vaccine 10 UNT/ML Injectable Suspension
- Acellular Pertussis Vaccine 0.046 MG/ML / Diphtheria Toxoid Vaccine 30 UNT/ML / Tetanus Toxoid Vaccine 10 UNT/ML Injectable Suspension

What constitutes an exclusion for DTaP Vaccination (Numerator 1)? (ICD-9-CM)

- Encephalitis and encephalomyelitis following immunization procedures 323.51

What constitutes an exclusion for DTaP Vaccination (Numerator 1)? (ICD-10-CM)

- Acute disseminated encephalitis G04.01

What constitutes an exclusion for DTaP Vaccination (Numerator 1)? (SNOMED-CT)

- Progressive neuronal degeneration of childhood 230363006

EXCLUSION OR EXCEPTION CRITERIA (NUMERATOR 2)

What constitutes an exclusion for IPV vaccination (Numerator 2)? (RxNorm)

- Poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / Poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / Poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML Injectable Solution
- 0.5 ML Poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / Poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / Poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML Prefilled Syringe
- Neomycin 3.5 MG/ML
- Neomycin 0.0035 MG/MG
- Neomycin 25 MG/ML
- Neomycin 0.005 MG/MG
- Neomycin 40 MG/ML
- Neomycin 3.3 MG/ML
- Neomycin 1.75 MG/ML
- Neomycin 5 MG/ML
- Neomycin 250 MG/ML
- *Unknown description*
- Streptomycin 400 MG/ML
- Polymyxin B 10000 UNT/ML
- Polymyxin B 10 UNT/MG
- Polymyxin B 16250 UNT/ML
- Polymyxin B 5 UNT/MG
- Neomycin 2.5 MG/ML
- Neomycin 20 MG/ML

EXCLUSION OR EXCEPTION CRITERIA (NUMERATOR 3)

What constitutes an exclusion for measles, mumps, and/or rubella vaccination (Numerator 3)? (RxNorm)

- Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML Injectable Solution
- Mumps Virus Vaccine Live, Jeryl Lynn Strain 40000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML Injectable Solution
- Mumps Virus Vaccine Live, Jeryl Lynn Strain 40000 UNT/ML Injectable Solution
- Mumps Virus Vaccine Live, Jeryl Lynn Strain 40000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML Injectable Solution
- Measles Virus Vaccine, Live Attenuated 2000 UNT/ML Injectable Solution
- Measles Vaccine 2000 UNT/ML Injectable Solution
- Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 UNT/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 25000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML Injectable Solution

What constitutes an exclusion for measles, mumps, and/or rubella vaccination (Numerator 3)? (RxNorm)

- Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 UNT/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 40000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML / Varicella Virus Vaccine Live (Oka-Merck) strain 20000 UNT/ML Injectable Solution
- Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML Injectable Solution
- Mumps Virus Vaccine Live, Jeryl Lynn Strain 40000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML Injectable Solution

What constitutes an exclusion for measles, mumps, and/or rubella vaccination (Numerator 3)? (ICD-9-CM)

• Hodgkin's Disease	201
• Other malignant neoplasms of lymphoid and histiocytic tissue	202
• Multiple myeloma and immunoproliferative neoplasms	203
• Human immunodeficiency virus (HIV) disease	042
• Asymptomatic human immunodeficiency virus (HIV) infection status	V08
• Disorders involving the immune mechanism	279
• Lymphosarcoma and reticulosarcoma and other specified malignant tumors of lymphatic tissue	200
• Lymphoid leukemia	204
• Myeloid leukemia	205
• Monocytic leukemia	206
• Other specified leukemia	207
• Leukemia of unspecified cell type	208

What constitutes an exclusion for measles, mumps, and/or rubella vaccination (Numerator 3)? (ICD-10-CM)

• Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue	C96
• <i>Unknown description</i>	C96.1
• <i>Unknown description</i>	C96.3
• Other specified malignant neoplasms of lymphoid, haematopoietic and related tissue	C96.7
• Asymptomatic human immunodeficiency virus [HIV] infection status	Z21
• <i>Unknown description</i>	E88.32
• Other specified metabolic disorders	E88.8
• Generalized idiopathic epilepsy and epileptic syndromes	G40.3
• Fourth [trochlear] nerve palsy	H49.1
• Myeloid leukemia	C92
• Acute myeloid leukemia	C92.5
• <i>Unknown description</i>	C93.91
• Other leukemias of specified cell type	C94
• Multiple myeloma and malignant plasma cells neoplasm	C90
• Multiple myeloma	C90.0
• Lymphoid leukemia	C91

What constitutes an exclusion for measles, mumps, and/or rubella vaccination (Numerator 3)? (SNOMED-CT)

- 18-p syndrome with associated immunodeficiency (disorder)
- Accelerated phase chronic myeloid leukemia (disorder)

What constitutes an exclusion for measles, mumps, and/or rubella vaccination (Numerator 3)? (SNOMED-CT)

- Acquired C1 esterase inhibitor deficiency (disorder)
- Acquired immune deficiency syndrome (AIDS) (disorder)
- Acquired immunodeficiency syndrome (AIDS) with dermatomycosis (disorder)
- Acquired immunodeficiency syndrome (AIDS) with Salmonella infection (disorder)
- Acquired neutropenia in newborn (disorder)
- Acute biphenotypic leukemia (disorder)
- Acute eosinophilic leukemia (disorder)
- Acute leukemia in remission (disorder)
- Acute leukemia, disease (disorder)
- Acute lymphoblastic leukemia, transitional pre-B-cell (disorder)
- Acute lymphoid leukemia in remission (disorder)
- Acute lymphoid leukemia, disease (disorder)
- Acute megakaryoblastic leukemia (disorder)
- Acute monoblastic leukemia (disorder)
- Acute monocytic leukemia in remission (disorder)
- Acute monocytic leukemia, FAB M5b (disorder)
- Acute monocytic/monoblastic leukemia (disorder)
- Acute myelofibrosis (disorder)
- Acute myeloid leukemia in remission (disorder)
- Acute myeloid leukemia with maturation, FAB M2 (disorder)
- Acute myeloid leukemia with maturation, FAB M2, in remission (disorder)
- Acute myeloid leukemia without maturation, FAB M1 (disorder)
- Acute myeloid leukemia, disease (disorder)
- Acute myeloid leukemia, minimal differentiation, FAB M0 (disorder)
- Acute myelomonocytic leukemia - eosinophilic variant (disorder)
- Acute myelomonocytic leukemia, FAB M4 (disorder)
- Acute myelomonocytic leukemia, FAB M4, in remission (disorder)
- Acute neutrophilia (disorder)
- Acute promyelocytic leukemia - hypogranular variant (disorder)
- Acute promyelocytic leukemia, FAB M3 (disorder)
- Acute promyelocytic leukemia, FAB M3, in remission (disorder)
- Adenosine deaminase deficiency (disorder)
- Adult T-cell leukemia (disorder)
- Adult T-cell leukemia/lymphoma (disorder)
- African Burkitt's lymphoma (disorder)
- Age-related immunodeficiency (disorder)
- Aggressive NK-cell leukemia involving skin (disorder)
- Agranulocytic angina (disorder)
- Agranulocytopenic disorder (disorder)
- Agranulocytosis (disorder)
- Agranulocytosis associated with AIDS (disorder)
- Aleukemic leukemia (disorder)

What constitutes an exclusion for measles, mumps, and/or rubella vaccination (Numerator 3)? (SNOMED-CT)

- Aleukemic leukemia in remission (disorder)
- Aleukemic lymphoid leukemia (disorder)
- Aleukemic lymphoid leukemia in remission (disorder)
- Aleukemic monocytic leukemia (disorder)
- Aleukemic myeloid leukemia (disorder)
- Alloimmune neonatal neutropenia (disorder)
- Alpha heavy chain disease (disorder)
- Alpha heavy chain disease, enteric form (disorder)
- Alpha heavy chain disease, respiratory form (disorder)
- Alternative pathway deficiency (disorder)
- Anaphylotoxin inactivator deficiency (disorder)
- Anaplastic large T-cell systemic malignant lymphoma (disorder)
- Angiocentric NK/T-cell malignant lymphoma involving skin (disorder)
- Angioendotheliomatosis (disorder)
- Angioimmunoblastic T-cell lymphoma (disorder)
- Anti-haemophilus influenzae B polysaccharide antibody deficiency (disorder)
- Anti-meningococcal polysaccharide A antibody deficiency (disorder)
- Anti-meningococcal polysaccharide C antibody deficiency (disorder)
- Anti-pneumococcal polysaccharide antibody deficiency (disorder)
- Anti-polysaccharide antibody deficiency (disorder)
- Anti-protein antibody deficiency (disorder)
- Anti-staphylococcal antibody deficiency (disorder)
- Aplasia of thymus gland with immunodeficiency (disorder)
- Asymptomatic human immunodeficiency virus infection (disorder)
- Asymptomatic human immunodeficiency virus infection in pregnancy (disorder)
- Asymptomatic multiple myeloma (disorder)
- Asymptomatic multiple myeloma (disorder)
- Asymptomatic multiple myeloma (disorder)
- Ataxia-telangiectasia syndrome (disorder)
- Atypical chronic myeloid leukemia (disorder)
- Atypical hairy cell leukemia (disorder)
- Autoimmune neutropenia (disorder)
- Autosomal agammaglobulinemia with absent B-cells (disorder)
- Autosomal recessive SCID (disorder)
- Autosomal recessive severe combined immunodeficiency (disorder)
- Basophilic leukemia (disorder)
- B-cell acute lymphoblastic leukemia (disorder)
- B-cell chronic lymphocytic leukemia (disorder)
- B-cell chronic lymphocytic leukemia variant (disorder)
- B-cell lymphoma (disorder)
- B-cell prolymphocytic leukemia (disorder)
- Benign combined immunodeficiency (disorder)

What constitutes an exclusion for measles, mumps, and/or rubella vaccination (Numerator 3)? (SNOMED-CT)

- Blastic phase chronic myeloid leukemia (disorder)
- Bloom syndrome (disorder)
- B-lymphocyte immunodeficiency (disorder)
- Bovine viral leukosis (disorder)
- Bullous mycosis fungoides (disorder)
- Burkitt's lymphoma (disorder)
- Burkitt's lymphoma associated with AIDS (disorder)
- Burkitt's lymphoma of intra-abdominal lymph nodes (disorder)
- Burkitt's lymphoma of intrapelvic lymph nodes (disorder)
- Burkitt's lymphoma of intrathoracic lymph nodes (disorder)
- Burkitt's lymphoma of lymph nodes of axilla and upper limb (disorder)
- Burkitt's lymphoma of lymph nodes of head, face and neck (disorder)
- Burkitt's lymphoma of lymph nodes of inguinal region and lower limb (disorder)
- Burkitt's lymphoma of lymph nodes of multiple sites (disorder)
- Burkitt's lymphoma of spleen (disorder)
- Burkitt's lymphoma of unspecified site (disorder)
- Burkitt's tumor of extranodal AND/OR solid organ site (disorder)
- Burkitt's tumor of intra-abdominal lymph nodes (disorder)
- Burkitt's tumor of lymph nodes of head, face AND/OR neck (disorder)
- Burkitt's tumor of lymph nodes of multiple sites (disorder)
- Burkitt's tumor of spleen (disorder)
- CD-30 negative cutaneous T-cell lymphoma (disorder)
- CD-30 negative pleomorphic large T-cell cutaneous lymphoma (disorder)
- CD-30 negative T-immunoblastic cutaneous lymphoma (disorder)
- CD-30 positive anaplastic large T-cell cutaneous lymphoma (disorder)
- CD-30 positive pleomorphic large T-cell cutaneous lymphoma (disorder)
- Centromeric instability of chromosomes 1,9 and 16 and immunodeficiency (disorder)
- Chediak-Higashi syndrome (disorder)
- Chemotherapy-induced neutropenia (disorder)
- Chloramphenicol-induced neutropenia (disorder)
- Chloroma (disorder)
- Chromosome 18 syndromes and antibody deficiency (disorder)
- Chromosome 22 abnormalities with hypogammaglobulinemia (disorder)
- Chronic benign neutropenia (disorder)
- Chronic benign neutropenia of childhood (disorder)
- Chronic eosinophilic leukemia (disorder)
- Chronic familial neutropenia (disorder)
- Chronic granulomatous disease (disorder)
- Chronic granulomatous disease, type I (disorder)
- Chronic granulomatous disease, type IA (disorder)
- Chronic granulomatous disease, type II (disorder)
- Chronic granulomatous disease, type IIA (disorder)

What constitutes an exclusion for measles, mumps, and/or rubella vaccination (Numerator 3)? (SNOMED-CT)

- Chronic granulomatous disease, type III (disorder)
- Chronic granulomatous disease, type IV (disorder)
- Chronic granulomatous disease, type IVA (disorder)
- Chronic hypoplastic neutropenia (disorder)
- Chronic idiopathic immunoneutropenia in adults (disorder)
- Chronic idiopathic neutropenia (disorder)
- Chronic leukemia in remission (disorder)
- Chronic leukemia, disease (disorder)
- Chronic lymphocytic prolymphocytic leukemia syndrome (disorder)
- Chronic lymphoid leukemia in remission (disorder)
- Chronic lymphoid leukemia, disease (disorder)
- Chronic monocytic leukemia (disorder)
- Chronic myeloid leukemia in lymphoid blast crisis (disorder)
- Chronic myeloid leukemia in myeloid blast crisis (disorder)
- Chronic myeloid leukemia in remission (disorder)
- Chronic myeloid leukemia, disease (disorder)
- Chronic myelomonocytic leukemia (disorder)
- Chronic neutrophilia (disorder)
- Chronic neutrophilic leukemia (disorder)
- Classical complement pathway abnormality (disorder)
- Combined complement 6 and 7 deficiencies (disorder)
- Combined immunodeficiency disease (disorder)
- Combined immunoglobulin G2 and G4 deficiency (disorder)
- Combined phagocytic defect (disorder)
- Common acute lymphoblastic leukemia (disorder)
- Common variable agammaglobulinemia (disorder)
- Complement 1q beta chain deficiency (disorder)
- Complement 1q deficiency (disorder)
- Complement 1q dysfunction (disorder)
- Complement 1r deficiency (disorder)
- Complement 1s deficiency (disorder)
- Complement 2 deficiency (disorder)
- Complement 3 deficiency (disorder)
- Complement 4 binding protein deficiency (disorder)
- Complement 4 deficiency (disorder)
- Complement 4A deficiency (disorder)
- Complement 4B deficiency (disorder)
- Complement 5 deficiency (disorder)
- Complement 5 dysfunction (disorder)
- Complement 5a inhibitor deficiency (disorder)
- Complement 6 deficiency (disorder)
- Complement 7 deficiency (disorder)

What constitutes an exclusion for measles, mumps, and/or rubella vaccination (Numerator 3)? (SNOMED-CT)

- Complement 8 alpha-gamma deficiency (disorder)
- Complement 8 beta chain deficiency (disorder)
- Complement 8 beta chain dysfunction (disorder)
- Complement 9 deficiency (disorder)
- Complement abnormality (disorder)
- Complement component deficiency (disorder)
- Complement deficiency disease (disorder)
- Complement receptor 1 deficiency (disorder)
- Complement receptor 3 deficiency (disorder)
- Complement receptor deficiency (disorder)
- Complement regulatory factor defect (disorder)
- Compound leukemias (disorder)
- Congenital agammaglobulinemia (disorder)
- Congenital dysphagocytosis (disorder)
- Congenital hypergammaglobulinemia (disorder)
- Congenital immunodeficiency disease (disorder)
- Congenital immunodeficiency involving the hematopoietic system (disorder)
- Congenital leukocyte adherence deficiency (disorder)
- Congenital neutropenia (disorder)
- Corticosteroid-induced neutrophilia (disorder)
- Cutaneous CD30+ lymphoproliferative disorder (disorder)
- Cutaneous/peripheral T-cell lymphoma (disorder)
- Cyclic neutropenia in Gray Collie dogs (disorder)
- Cyclical neutropenia (disorder)
- De Vaal's syndrome (disorder)
- Decay accelerating factor deficiency (disorder)
- Defective immunoglobulin glycosylation (disorder)
- Defective phagocytic cell adhesion (disorder)
- Defective phagocytic cell chemotaxis (disorder)
- Defective phagocytic cell killing (disorder)
- Defective phagocytic cell opsonization (disorder)
- Deletion of X-chromosome and hypogammaglobulinemia (disorder)
- Delta heavy chain disease (disorder)
- Diffuse high grade B-cell lymphoma (disorder)
- Diffuse large B-cell lymphoma (nodal/systemic with skin involvement) (disorder)
- Diffuse low grade B-cell lymphoma (disorder)
- Diffuse malignant lymphoma - centroblastic (disorder)
- Diffuse malignant lymphoma - centroblastic polymorphic (disorder)
- Diffuse malignant lymphoma - centroblastic-centrocytic (disorder)
- Diffuse malignant lymphoma - large cleaved cell (disorder)
- Diffuse malignant lymphoma - large non-cleaved cell (disorder)
- Diffuse malignant lymphoma - small non-cleaved cell (disorder)

What constitutes an exclusion for measles, mumps, and/or rubella vaccination (Numerator 3)? (SNOMED-CT)

- Diffuse non-Hodgkin's lymphoma (disorder)
- Diffuse non-Hodgkin's lymphoma undifferentiated (diffuse) (disorder)
- Diffuse non-Hodgkin's lymphoma, immunoblastic (disorder)
- Diffuse non-Hodgkin's lymphoma, large cell (disorder)
- Diffuse non-Hodgkin's lymphoma, lymphoblastic (disorder)
- Diffuse non-Hodgkin's lymphoma, small cell (disorder)
- Diffuse non-Hodgkin's lymphoma, small cleaved cell (disorder)
- Diffuse non-Hodgkin's lymphoma, undifferentiated (disorder)
- Disorder of complement (disorder)
- Disorder of phagocytic cell number (disorder)
- Dose-related drug-induced neutropenia (disorder)
- Drug-induced immunodeficiency (disorder)
- Drug-induced neutropenia (disorder)
- Drug-induced neutrophilia (disorder)
- Dysplasia of thymus gland with immunodeficiency (disorder)
- Enteropathy-associated T-cell lymphoma (disorder)
- Epsilon heavy chain disease (disorder)
- Erythrodermic mycosis fungoides (disorder)
- Erythroleukemia, FAB M6 (disorder)
- Erythroleukemia, FAB M6 in remission (disorder)
- Extranodal NK/T-cell lymphoma, nasal type (disorder)
- Factor B deficiency (disorder)
- Factor D deficiency (disorder)
- Factor H deficiency (disorder)
- Factor I deficiency (disorder)
- Familial C3B inhibitor deficiency syndrome (disorder)
- Familial hemophagocytic lymphohistiocytosis (disorder)
- Familial immunoglobulin hypercatabolism (disorder)
- Familial neutropenia (disorder)
- Febrile neutropenia (disorder)
- Follicular center B-cell lymphoma (nodal/systemic with skin involvement) (disorder)
- Follicular low grade B-cell lymphoma (disorder)
- Follicular malignant lymphoma - large cell (disorder)
- Follicular malignant lymphoma - mixed cell type (disorder)
- Follicular malignant lymphoma - small cleaved cell (disorder)
- Follicular mucinosis type mycosis fungoides (disorder)
- Follicular non-Hodgkin's lymphoma (disorder)
- Follicular non-Hodgkin's lymphoma, large cell (disorder)
- Follicular non-Hodgkin's lymphoma, mixed small cleaved cell and large cell (disorder)
- Follicular non-Hodgkin's lymphoma, small cleaved cell (disorder)
- Follicular non-Hodgkin's mixed small cleaved and large cell lymphoma (disorder)
- Functional disorders of polymorphonuclear neutrophils (disorder)

What constitutes an exclusion for measles, mumps, and/or rubella vaccination (Numerator 3)? (SNOMED-CT)

- Gamma heavy chain disease (disorder)
- Gastric lymphoma (disorder)
- Gluthathione peroxidase deficiency (disorder)
- Gluthathione synthetase deficiency (disorder)
- Granulocytic sarcoma (disorder)
- Granulocytic sarcoma affecting skin (disorder)
- Granulomatous mycosis fungoides (disorder)
- Hairy cell leukemia (disorder)
- Hairy cell leukemia of spleen (disorder)
- Hairy cell leukemia variant (disorder)
- Heavy chain disease (disorder)
- Hemolytic erythrophagocytic syndrome (disorder)
- Hemophagocytic lymphohistiocytosis (disorder)
- Hereditary angioneurotic edema (disorder)
- Hereditary C1 esterase inhibitor deficiency - deficient factor (disorder)
- Hereditary C1 esterase inhibitor deficiency - dysfunctional factor (disorder)
- Hereditary neutrophilia (disorder)
- High grade B-cell lymphoma (disorder)
- High grade T-cell lymphoma (disorder)
- Hodgkin lymphoma, lymphocyte-rich (disorder)
- Hodgkin lymphoma, nodular lymphocyte predominance (disorder)
- Hodgkin's disease (disorder)
- Hodgkin's disease affecting skin (disorder)
- Hodgkin's disease in remission (disorder)
- Hodgkin's disease of extranodal AND/OR solid organ site (disorder)
- Hodgkin's disease of intra-abdominal lymph nodes (disorder)
- Hodgkin's disease of intrapelvic lymph nodes (disorder)
- Hodgkin's disease of intrathoracic lymph nodes (disorder)
- Hodgkin's disease of lymph nodes of axilla AND/OR upper limb (disorder)
- Hodgkin's disease of lymph nodes of head, face AND/OR neck (disorder)
- Hodgkin's disease of lymph nodes of inguinal region AND/OR lower limb (disorder)
- Hodgkin's disease of lymph nodes of multiple sites (disorder)
- Hodgkin's disease of spleen (disorder)
- Hodgkin's disease, lymphocytic depletion (disorder)
- Hodgkin's disease, lymphocytic depletion of extranodal AND/OR solid organ site (disorder)
- Hodgkin's disease, lymphocytic depletion of intra-abdominal lymph nodes (disorder)
- Hodgkin's disease, lymphocytic depletion of intrapelvic lymph nodes (disorder)
- Hodgkin's disease, lymphocytic depletion of intrathoracic lymph nodes (disorder)
- Hodgkin's disease, lymphocytic depletion of lymph nodes of axilla and upper limb (disorder)
- Hodgkin's disease, lymphocytic depletion of lymph nodes of axilla AND/OR upper limb (disorder)
- Hodgkin's disease, lymphocytic depletion of lymph nodes of head (disorder)
- Hodgkin's disease, lymphocytic depletion of lymph nodes of head, face and neck (disorder)

What constitutes an exclusion for measles, mumps, and/or rubella vaccination (Numerator 3)? (SNOMED-CT)

- Hodgkin's disease, lymphocytic depletion of lymph nodes of head, face AND/OR neck (disorder)
- Hodgkin's disease, lymphocytic depletion of lymph nodes of inguinal region and lower limb (disorder)
- Hodgkin's disease, lymphocytic depletion of lymph nodes of inguinal region AND/OR lower limb (disorder)
- Hodgkin's disease, lymphocytic depletion of lymph nodes of multiple sites (disorder)
- Hodgkin's disease, lymphocytic depletion of spleen (disorder)
- Hodgkin's disease, lymphocytic depletion, diffuse fibrosis (disorder)
- Hodgkin's disease, lymphocytic depletion, reticular type (disorder)
- Hodgkin's disease, lymphocytic predominance - diffuse (disorder)
- Hodgkin's disease, lymphocytic predominance - nodular (disorder)
- Hodgkin's disease, lymphocytic-histiocytic predominance of extranodal AND/OR solid organ site (disorder)
- Hodgkin's disease, lymphocytic-histiocytic predominance of intra-abdominal lymph nodes (disorder)
- Hodgkin's disease, lymphocytic-histiocytic predominance of intrapelvic lymph nodes (disorder)
- Hodgkin's disease, lymphocytic-histiocytic predominance of intrathoracic lymph nodes (disorder)
- Hodgkin's disease, lymphocytic-histiocytic predominance of lymph nodes of head, face and neck (disorder)
- Hodgkin's disease, lymphocytic-histiocytic predominance of lymph nodes of axilla and upper limb (disorder)
- Hodgkin's disease, lymphocytic-histiocytic predominance of lymph nodes of inguinal region and lower limb (disorder)
- Hodgkin's disease, lymphocytic-histiocytic predominance of lymph nodes of multiple sites (disorder)
- Hodgkin's disease, lymphocytic-histiocytic predominance of lymph nodes of axilla AND/OR upper limb (disorder)
- Hodgkin's disease, lymphocytic-histiocytic predominance of lymph nodes of head, face AND/OR neck (disorder)
- Hodgkin's disease, lymphocytic-histiocytic predominance of lymph nodes of inguinal region AND/OR lower limb (disorder)
- Hodgkin's disease, lymphocytic-histiocytic predominance of spleen (disorder)
- Hodgkin's disease, mixed cellularity (disorder)
- Hodgkin's disease, mixed cellularity of extranodal AND/OR solid organ site (disorder)
- Hodgkin's disease, mixed cellularity of intra-abdominal lymph nodes (disorder)
- Hodgkin's disease, mixed cellularity of intrapelvic lymph nodes (disorder)
- Hodgkin's disease, mixed cellularity of intrathoracic lymph nodes (disorder)
- Hodgkin's disease, mixed cellularity of lymph nodes of axilla and upper limb (disorder)
- Hodgkin's disease, mixed cellularity of lymph nodes of axilla AND/OR upper limb (disorder)
- Hodgkin's disease, mixed cellularity of lymph nodes of head, face and neck (disorder)
- Hodgkin's disease, mixed cellularity of lymph nodes of head, face AND/OR neck (disorder)
- Hodgkin's disease, mixed cellularity of lymph nodes of inguinal region and lower limb (disorder)
- Hodgkin's disease, mixed cellularity of lymph nodes of inguinal region AND/OR lower limb (disorder)
- Hodgkin's disease, mixed cellularity of lymph nodes of multiple sites (disorder)
- Hodgkin's disease, mixed cellularity of spleen (disorder)
- Hodgkin's disease, nodular sclerosis (disorder)
- Hodgkin's disease, nodular sclerosis - cellular phase (disorder)
- Hodgkin's disease, nodular sclerosis - lymphocytic depletion (disorder)
- Hodgkin's disease, nodular sclerosis - lymphocytic predominance (disorder)
- Hodgkin's disease, nodular sclerosis - mixed cellularity (disorder)
- Hodgkin's disease, nodular sclerosis of extranodal AND/OR solid organ site (disorder)
- Hodgkin's disease, nodular sclerosis of intra-abdominal lymph nodes (disorder)
- Hodgkin's disease, nodular sclerosis of intrapelvic lymph nodes (disorder)

What constitutes an exclusion for measles, mumps, and/or rubella vaccination (Numerator 3)? (SNOMED-CT)

- Hodgkin's disease, nodular sclerosis of intrathoracic lymph nodes (disorder)
- Hodgkin's disease, nodular sclerosis of lymph nodes of axilla and upper limb (disorder)
- Hodgkin's disease, nodular sclerosis of lymph nodes of axilla AND/OR upper limb (disorder)
- Hodgkin's disease, nodular sclerosis of lymph nodes of head, face and neck (disorder)
- Hodgkin's disease, nodular sclerosis of lymph nodes of head, face AND/OR neck (disorder)
- Hodgkin's disease, nodular sclerosis of lymph nodes of inguinal region and lower limb (disorder)
- Hodgkin's disease, nodular sclerosis of lymph nodes of inguinal region AND/OR lower limb (disorder)
- Hodgkin's disease, nodular sclerosis of lymph nodes of multiple sites (disorder)
- Hodgkin's disease, nodular sclerosis of spleen (disorder)
- Hodgkin's granuloma (disorder)
- Hodgkin's granuloma of extranodal AND/OR solid organ site (disorder)
- Hodgkin's granuloma of intra-abdominal lymph nodes (disorder)
- Hodgkin's granuloma of intrapelvic lymph nodes (disorder)
- Hodgkin's granuloma of intrathoracic lymph nodes (disorder)
- Hodgkin's granuloma of lymph nodes of axilla and upper limb (disorder)
- Hodgkin's granuloma of lymph nodes of axilla AND/OR upper limb (disorder)
- Hodgkin's granuloma of lymph nodes of head, face and neck (disorder)
- Hodgkin's granuloma of lymph nodes of head, face AND/OR neck (disorder)
- Hodgkin's granuloma of lymph nodes of inguinal region and lower limb (disorder)
- Hodgkin's granuloma of lymph nodes of inguinal region AND/OR lower limb (disorder)
- Hodgkin's granuloma of lymph nodes of multiple sites (disorder)
- Hodgkin's granuloma of spleen (disorder)
- Hodgkin's granuloma of unspecified site (disorder)
- Hodgkin's paraganuloma of extranodal AND/OR solid organ site (disorder)
- Hodgkin's paraganuloma of intra-abdominal lymph nodes (disorder)
- Hodgkin's paraganuloma of intrapelvic lymph nodes (disorder)
- Hodgkin's paraganuloma of intrathoracic lymph nodes (disorder)
- Hodgkin's paraganuloma of lymph nodes of axilla AND/OR upper limb (disorder)
- Hodgkin's paraganuloma of lymph nodes of head, face AND/OR neck (disorder)
- Hodgkin's paraganuloma of lymph nodes of inguinal region AND/OR lower limb (disorder)
- Hodgkin's paraganuloma of lymph nodes of multiple sites (disorder)
- Hodgkin's paraganuloma of spleen (disorder)
- Hodgkin's sarcoma (disorder)
- Hodgkin's sarcoma of extranodal AND/OR solid organ site (disorder)
- Hodgkin's sarcoma of intra-abdominal lymph nodes (disorder)
- Hodgkin's sarcoma of intrapelvic lymph nodes (disorder)
- Hodgkin's sarcoma of intrathoracic lymph nodes (disorder)
- Hodgkin's sarcoma of lymph nodes of axilla and upper limb (disorder)
- Hodgkin's sarcoma of lymph nodes of axilla AND/OR upper limb (disorder)
- Hodgkin's sarcoma of lymph nodes of head, face AND/OR neck (disorder)
- Hodgkin's sarcoma of lymph nodes of inguinal region and lower limb (disorder)
- Hodgkin's sarcoma of lymph nodes of inguinal region AND/OR lower limb (disorder)

What constitutes an exclusion for measles, mumps, and/or rubella vaccination (Numerator 3)? (SNOMED-CT)

- Hodgkin's sarcoma of lymph nodes of multiple sites (disorder)
- Hodgkin's sarcoma of spleen (disorder)
- Hodgkin's sarcoma of unspecified site (disorder)
- Hodgkin's, lymphocytic-histiocytic predominance of spleen (disorder)
- Homologous restriction factor deficiency (disorder)
- Human immunodeficiency virus (HIV) disease resulting in Burkitt's lymphoma (disorder)
- Hypergranular promyelocytic leukemia (disorder)
- Hyperimmunoglobulin M syndrome (disorder)
- Hypopigmentation-immunodeficiency disease (disorder)
- IgA monoclonal gammopathy of uncertain significance (disorder)
- IgA myeloma (disorder)
- IgD monoclonal gammopathy of uncertain significance (disorder)
- IgD myeloma (disorder)
- IgG monoclonal gammopathy of uncertain significance (disorder)
- IgG myeloma (disorder)
- IgM monoclonal gammopathy of uncertain significance (disorder)
- Immune neutropenia (disorder)
- Immunoblastic lymphoma associated with AIDS (disorder)
- Immunodeficiency associated with chromosomal abnormality (disorder)
- Immunodeficiency associated with multiple organ system abnormalities (disorder)
- Immunodeficiency disorder (disorder)
- Immunodeficiency following hereditary defective response to Epstein-Barr virus (disorder)
- Immunodeficiency secondary to chemotherapy (disorder)
- Immunodeficiency secondary to corticosteroids (disorder)
- Immunodeficiency secondary to neoplasm (disorder)
- Immunodeficiency secondary to radiation therapy (disorder)
- Immunodeficiency secondary to trauma (disorder)
- Immunodeficiency with major anomalies (disorder)
- Immunodeficiency with multicarboxylase deficiency (disorder)
- Immunodeficiency with thymoma (disorder)
- Immunoglobulin A deficiency (disorder)
- Immunoglobulin A1 deficiency (disorder)
- Immunoglobulin A2 deficiency (disorder)
- Immunoglobulin deficiency (disorder)
- Immunoglobulin G1 deficiency (disorder)
- Immunoglobulin G2 deficiency (disorder)
- Immunoglobulin G3 deficiency (disorder)
- Immunoglobulin G4 deficiency (disorder)
- Immunoglobulin heavy chain deficiency (disorder)
- Immunoglobulin hypercatabolism (disorder)
- Immunoglobulin light chain deficiency (disorder)
- Immunoglobulin subclass deficiency (disorder)

What constitutes an exclusion for measles, mumps, and/or rubella vaccination (Numerator 3)? (SNOMED-CT)

- Immunoglobulin-associated molecule deficiency (disorder)
- Immunoglobulinemia with isolated somatotropin deficiency (disorder)
- Indolent multiple myeloma (disorder)
- Intermediate grade B-cell lymphoma (disorder)
- Intraocular non-Hodgkin malignant lymphoma (disorder)
- Isoimmune neutropenia (disorder)
- Job's syndrome (disorder)
- Juvenile chronic myeloid leukemia (disorder)
- Kappa light chain disease (disorder)
- Kappa light chain myeloma (disorder)
- Lambda light chain disease (disorder)
- Lambda light chain myeloma (disorder)
- Large cell anaplastic lymphoma (disorder)
- Large cell lymphoma of intrapelvic lymph nodes (disorder)
- Large granular lymphocytic leukemia (disorder)
- Lazy leukocyte syndrome (disorder)
- Lethal midline granuloma (disorder)
- Leukemia in remission (disorder)
- Leukemia of unspecified cell type (disorder)
- Leukemia, disease (disorder)
- Leukemic infiltration of skin (chronic T-cell lymphocytic leukemia) (disorder)
- Leukemic infiltration of skin (T-cell lymphoblastic leukemia) (disorder)
- Leukemic infiltration of skin (T-cell prolymphocytic leukemia) (disorder)
- Leukemic infiltration of skin in acute myeloid leukemia (disorder)
- Leukemic infiltration of skin in chronic myeloid leukemia (disorder)
- Leukemic infiltration of skin in hairy-cell leukemia (disorder)
- Leukemic infiltration of skin in monocytic leukemia (disorder)
- Leukemic infiltration of skin in myeloid leukemia (disorder)
- Leukemic reticuloendotheliosis of extranodal AND/OR solid organ site (disorder)
- Leukemic reticuloendotheliosis of intra-abdominal lymph nodes (disorder)
- Leukemic reticuloendotheliosis of intrapelvic lymph nodes (disorder)
- Leukemic reticuloendotheliosis of intrathoracic lymph nodes (disorder)
- Leukemic reticuloendotheliosis of lymph nodes of axilla and upper limb (disorder)
- Leukemic reticuloendotheliosis of lymph nodes of axilla AND/OR upper limb (disorder)
- Leukemic reticuloendotheliosis of lymph nodes of head, face and neck (disorder)
- Leukemic reticuloendotheliosis of lymph nodes of head, face AND/OR neck (disorder)
- Leukemic reticuloendotheliosis of lymph nodes of inguinal region and lower limb (disorder)
- Leukemic reticuloendotheliosis of lymph nodes of inguinal region AND/OR lower limb (disorder)
- Leukemic reticuloendotheliosis of lymph nodes of multiple sites (disorder)
- Leukemic reticuloendotheliosis of spleen (disorder)
- Leukocyte adhesion deficiency - type 1 (disorder)
- Leukocyte adhesion deficiency - type 2 (disorder)

What constitutes an exclusion for measles, mumps, and/or rubella vaccination (Numerator 3)? (SNOMED-CT)

- Leukocyte glucose-6-phosphate dehydrogenase deficiency (disorder)
- Light chain monoclonal gammopathy of uncertain significance (disorder)
- Light chain myeloma (disorder)
- Lipochrome histiocytosis - familial (disorder)
- Localized pagetoid reticulosis (disorder)
- Low grade B-cell lymphoma (disorder)
- Low grade T-cell lymphoma (disorder)
- Lymphocyte function antigen-1 defect (disorder)
- Lymphoepithelioid lymphoma (disorder)
- Lymphoid leukemia (disorder)
- Lymphoid leukemia in remission (disorder)
- Lymphoma of intestine (disorder)
- Lymphoma of kidney (disorder)
- Lymphoma of retina (disorder)
- Lymphoma of retroperitoneal space (disorder)
- Lymphoma with spill (disorder)
- Lymphomatoid papulosis (disorder)
- Lymphomatoid papulosis type A (CD-30 positive type) (disorder)
- Lymphomatoid papulosis type B - mycosis fungoides-like (disorder)
- Lymphomatoid papulosis type C (anaplastic large-cell lymphoma-like) (disorder)
- Lymphomatoid papulosis with Hodgkin's disease (disorder)
- Lymphomatoid papulosis-associated mycosis fungoides (disorder)
- Lymphopenic agammaglobulinemia - short-limbed dwarfism syndrome (disorder)
- Lymphoproliferative disease of turkey (disorder)
- Lymphoreticular tumor (disorder)
- Lymphosarcoma (disorder)
- Lymphosarcoma and reticulosarcoma (disorder)
- Lymphosarcoma of intra-abdominal lymph nodes (disorder)
- Lymphosarcoma of intrapelvic lymph nodes (disorder)
- Lymphosarcoma of intrathoracic lymph nodes (disorder)
- Lymphosarcoma of lymph nodes of axilla and upper limb (disorder)
- Lymphosarcoma of lymph nodes of head, face and neck (disorder)
- Lymphosarcoma of lymph nodes of inguinal region and lower limb (disorder)
- Lymphosarcoma of lymph nodes of multiple sites (disorder)
- Lymphosarcoma of spleen (disorder)
- Lymphosarcoma of unspecified site (disorder)
- Major histocompatibility complex class I deficiency (disorder)
- Major histocompatibility complex class II deficiency (disorder)
- Malignant lymphoma (disorder)
- Malignant lymphoma - centrocytic (disorder)
- Malignant lymphoma - lymphocytic, intermediate differentiation (disorder)
- Malignant lymphoma - lymphoplasmacytic (disorder)

What constitutes an exclusion for measles, mumps, and/or rubella vaccination (Numerator 3)? (SNOMED-CT)

- Malignant lymphoma - mixed small and large cell (disorder)
- Malignant lymphoma - small cleaved cell (disorder)
- Malignant lymphoma - small lymphocytic (disorder)
- Malignant lymphoma in remission (disorder)
- Malignant lymphoma of breast (disorder)
- Malignant lymphoma of extranodal AND/OR solid organ site (disorder)
- Malignant lymphoma of intra-abdominal lymph nodes (disorder)
- Malignant lymphoma of intrapelvic lymph nodes (disorder)
- Malignant lymphoma of intrathoracic lymph nodes (disorder)
- Malignant lymphoma of lymph nodes (disorder)
- Malignant lymphoma of lymph nodes of axilla AND/OR upper limb (disorder)
- Malignant lymphoma of lymph nodes of head, face AND/OR neck (disorder)
- Malignant lymphoma of lymph nodes of inguinal region AND/OR lower limb (disorder)
- Malignant lymphoma of lymph nodes of multiple sites (disorder)
- Malignant lymphoma of spleen (disorder)
- Malignant lymphoma of testis (disorder)
- Malignant lymphoma of the eye region (disorder)
- Malignant lymphoma of thyroid gland (disorder)
- Malignant lymphoma otherwise specified (disorder)
- Malignant lymphoma, centroblastic type, follicular (disorder)
- Malignant lymphoma, centroblastic-centrocytic, follicular (disorder)
- Malignant lymphoma, convoluted cell type (disorder)
- Malignant lymphoma, follicular center cell (disorder)
- Malignant lymphoma, follicular center cell, cleaved (disorder)
- Malignant lymphoma, follicular center cell, non-cleaved (disorder)
- Malignant lymphoma, large cell, polymorphous, immunoblastic (disorder)
- Malignant lymphoma, lymphocytic, poorly differentiated, nodular (disorder)
- Malignant lymphoma, mixed lymphocytic-histiocytic, nodular (disorder)
- Malignant plasma cell neoplasm, extramedullary plasmacytoma (disorder)
- Malignant tumor of lymphoid, hemopoietic AND/OR related tissue (disorder)
- Mannan-binding protein deficiency (disorder)
- Mantle cell B-cell lymphoma (nodal/systemic with skin involvement) (disorder)
- Mantle cell lymphoma of spleen (disorder)
- Marek's disease (disorder)
- Mast cell leukemia (disorder)
- Mature T-cell AND/OR NK cell neoplasm (disorder)
- Megakaryocytic leukemia (disorder)
- Megakaryocytic leukemia in remission (disorder)
- Metabolic neutropenia (disorder)
- Microcephaly, normal intelligence and immunodeficiency (disorder)
- Microglioma (disorder)
- Mixed cell type lymphosarcoma of intra-abdominal lymph nodes (disorder)

What constitutes an exclusion for measles, mumps, and/or rubella vaccination (Numerator 3)? (SNOMED-CT)

- Mixed cell type lymphosarcoma of intrapelvic lymph nodes (disorder)
- Mixed cell type lymphosarcoma of intrathoracic lymph nodes (disorder)
- Mixed cell type lymphosarcoma of lymph nodes of head, face, and neck (disorder)
- Monoclonal gammopathy of uncertain significance (disorder)
- Monocytic leukemia (disorder)
- Monocytoid B-cell lymphoma (disorder)
- Monosomy 22 and absence of immunoglobulin A (disorder)
- Mu heavy chain disease (disorder)
- Mucosa-associated lymphoid tissue (MALT) lymphoma of orbit (disorder)
- Mucosa-associated lymphoma (disorder)
- Multiple myeloma (disorder)
- Multiple myeloma in remission (disorder)
- Multiple solitary plasmacytomas (disorder)
- Mycosis fungoides (disorder)
- Mycosis fungoides of extranodal AND/OR solid organ site (disorder)
- Mycosis fungoides of intra-abdominal lymph nodes (disorder)
- Mycosis fungoides of intrapelvic lymph nodes (disorder)
- Mycosis fungoides of intrathoracic lymph nodes (disorder)
- Mycosis fungoides of lymph nodes of axilla AND/OR upper limb (disorder)
- Mycosis fungoides of lymph nodes of head, face AND/OR neck (disorder)
- Mycosis fungoides of lymph nodes of inguinal region AND/OR lower limb (disorder)
- Mycosis fungoides of lymph nodes of multiple sites (disorder)
- Mycosis fungoides of spleen (disorder)
- Mycosis fungoides with systemic infiltration (disorder)
- Myeloid leukemia (disorder)
- Myeloid leukemia in remission (disorder)
- Myeloid sarcoma in remission (disorder)
- Myeloid sarcoma, disease (disorder)
- Myelokathexis (disorder)
- Myelomonocytic leukemia (disorder)
- Myeloperoxidase deficiency (disorder)
- Neutropenia associated with AIDS (disorder)
- Neutropenia associated with autoimmune disease (disorder)
- Neutropenia associated with infectious disease (disorder)
- Neutropenia due to irradiation (disorder)
- Neutropenia with dysgranulopoiesis (disorder)
- Neutropenic disorder (disorder)
- Neutrophil lactoferrin deficiency (disorder)
- Neutrophil secondary granule deficiency (disorder)
- Neutrophilia (disorder)
- Neutrophilic leukemia (disorder)
- Neutrophilic leukemoid reaction (disorder)

What constitutes an exclusion for measles, mumps, and/or rubella vaccination (Numerator 3)? (SNOMED-CT)

- Nezelof's syndrome (disorder)
- Nodular high grade B-cell lymphoma (disorder)
- Nodular lymphoma (disorder)
- Nodular lymphoma of extranodal AND/OR solid organ site (disorder)
- Nodular lymphoma of intra-abdominal lymph nodes (disorder)
- Nodular lymphoma of intrapelvic lymph nodes (disorder)
- Nodular lymphoma of intrathoracic lymph nodes (disorder)
- Nodular lymphoma of lymph nodes of axilla and upper limb (disorder)
- Nodular lymphoma of lymph nodes of head, face and neck (disorder)
- Nodular lymphoma of lymph nodes of inguinal region and lower limb (disorder)
- Nodular lymphoma of lymph nodes of multiple sites (disorder)
- Nodular lymphoma of spleen (disorder)
- Nodular lymphoma of unspecified site (disorder)
- Nodular malignant lymphoma, lymphocytic - intermediate differentiation (disorder)
- Nodular malignant lymphoma, lymphocytic - well differentiated (disorder)
- Non dose-related drug-induced neutropenia (disorder)
- Non-Hodgkin lymphoma associated with Human immunodeficiency virus infection (disorder)
- Non-Hodgkin's lymphoma (disorder)
- Non-secretory myeloma (disorder)
- Null cell acute lymphoblastic leukemia (disorder)
- Orbital lymphoma (disorder)
- Osteosclerotic myeloma (disorder)
- Other lymphoid leukemia (disorder)
- Other malignant neoplasm of lymphoid and histiocytic tissue (disorder)
- Other myeloid leukemia (disorder)
- Other types of follicular non-Hodgkin's lymphoma (disorder)
- Pagetoid reticulosis (disorder)
- Patch/plaque stage mycosis fungoides (disorder)
- Peripheral T-cell lymphoma (disorder)
- Peripheral T-cell lymphoma - pleomorphic medium and large cell (disorder)
- Peripheral T-cell lymphoma - pleomorphic small cell (disorder)
- Phagocytic cell defect (disorder)
- Phagocytic cell dysfunction (disorder)
- Philadelphia chromosome-positive acute lymphoblastic leukemia (disorder)
- Plasma cell dyscrasia with polyneuropathy (disorder)
- Plasma cell leukemia in remission (disorder)
- Plasma cell leukemia, disease (disorder)
- Plasma cell myeloma/plasmacytoma (disorder)
- Plasma cell neoplasm (disorder)
- Plasmacytoma (disorder)
- Pleomorphic small/medium-sized cell cutaneous T-cell lymphoma (disorder)
- Poikilodermatous mycosis fungoides (disorder)

What constitutes an exclusion for measles, mumps, and/or rubella vaccination (Numerator 3)? (SNOMED-CT)

- Pre B-cell acute lymphoblastic leukemia (disorder)
- Pre B-cell acute lymphoblastic leukemia in remission (disorder)
- Precursor B-cell lymphoblastic lymphoma involving skin (disorder)
- Precursor T-cell neoplasm (disorder)
- Prethymic and thymic T-cell lymphoma/leukemia (disorder)
- Primary amyloidosis of light chain type (disorder)
- Primary cerebral lymphoma (disorder)
- Primary cutaneous anaplastic large cell B-cell lymphoma (disorder)
- Primary cutaneous B-cell lymphoma (disorder)
- Primary cutaneous CD30+ large T-cell lymphoma (disorder)
- Primary cutaneous diffuse large cell B-cell lymphoma (disorder)
- Primary cutaneous diffuse large cell B-cell lymphoma of the leg (disorder)
- Primary cutaneous follicular center B-cell lymphoma (disorder)
- Primary cutaneous immunocytoma (disorder)
- Primary cutaneous lymphoma (disorder)
- Primary cutaneous marginal zone B-cell lymphoma (disorder)
- Primary cutaneous plasmacytoma (disorder)
- Primary cutaneous T-cell lymphoma (disorder)
- Primary immune deficiency disorder (disorder)
- Primary immunoglobulin catabolism abnormality (disorder)
- Primary lymphoma of brain associated with AIDS (disorder)
- Primary malignant neoplasm (disorder)
- Primary splenic neutropenia (disorder)
- Proliferating angioendotheliomatosis (disorder)
- Prolymphocytic leukemia (disorder)
- Prolymphocytic lymphosarcoma (disorder)
- Properdin deficiency disease (disorder)
- Pseudoneutrophilia (disorder)
- Purine-nucleoside phosphorylase deficiency (disorder)
- Quantitative abnormality of granulocytes (disorder)
- Quantitative disorder of neutrophils (disorder)
- Relapsing chronic myeloid leukemia (disorder)
- Reticular dysgenesis (disorder)
- Reticular dysgenesis with congenital aleukocytosis (disorder)
- Reticulosarcoma (disorder)
- Reticulosarcoma associated with AIDS (disorder)
- Reticulosarcoma of intra-abdominal lymph nodes (disorder)
- Reticulosarcoma of intrapelvic lymph nodes (disorder)
- Reticulosarcoma of intrathoracic lymph nodes (disorder)
- Reticulosarcoma of lymph nodes of axilla and upper limb (disorder)
- Reticulosarcoma of lymph nodes of head, face and neck (disorder)
- Reticulosarcoma of lymph nodes of inguinal region and lower limb (disorder)

What constitutes an exclusion for measles, mumps, and/or rubella vaccination (Numerator 3)? (SNOMED-CT)

- Reticulosarcoma of lymph nodes of multiple sites (disorder)
- Reticulosarcoma of spleen (disorder)
- Reticulosarcoma of unspecified site (disorder)
- Richter's syndrome (disorder)
- Secondary immune deficiency disorder (disorder)
- Secretory piece deficiency (disorder)
- Selective immunoglobulin A deficiency (disorder)
- Selective immunoglobulin D deficiency (disorder)
- Selective immunoglobulin E deficiency (disorder)
- Selective immunoglobulin G deficiency (disorder)
- Selective immunoglobulin M and immunoglobulin A deficiency (disorder)
- Selective immunoglobulin M deficiency (disorder)
- Severe combined immunodeficiency (SCID) due to absent adenosine deaminase (disorder)
- Severe combined immunodeficiency (SCID) due to absent class II HLA antigens (disorder)
- Severe combined immunodeficiency (SCID) due to absent IL-2 receptor (disorder)
- Severe combined immunodeficiency (SCID) due to absent interleukin (IL)-2 production (disorder)
- Severe combined immunodeficiency (SCID) due to absent lymphoid stem cells (disorder)
- Severe combined immunodeficiency (SCID) due to absent peripheral T cell maturation (disorder)
- Severe combined immunodeficiency (SCID) due to absent T cell receptor (disorder)
- Severe combined immunodeficiency disease (disorder)
- Severe combined immunodeficiency with low or normal B-cell numbers (disorder)
- Severe combined immunodeficiency with low T- and B-cell numbers (disorder)
- Severe combined immunodeficiency with maternofetal engraftment (disorder)
- Severe combined immunodeficiency with reticular dysgenesis (disorder)
- Sezary's disease (disorder)
- Sezary's disease of extranodal AND/OR solid organ site (disorder)
- Sezary's disease of intra-abdominal lymph nodes (disorder)
- Sezary's disease of intrapelvic lymph nodes (disorder)
- Sezary's disease of intrathoracic lymph nodes (disorder)
- Sezary's disease of lymph nodes of axilla and upper limb (disorder)
- Sezary's disease of lymph nodes of head, face and neck (disorder)
- Sezary's disease of lymph nodes of head, face AND/OR neck (disorder)
- Sezary's disease of lymph nodes of inguinal region and lower limb (disorder)
- Sezary's disease of lymph nodes of inguinal region AND/OR lower limb (disorder)
- Sezary's disease of lymph nodes of multiple sites (disorder)
- Sezary's disease of skin (disorder)
- Sezary's disease of spleen (disorder)
- Shwachman syndrome (disorder)
- Small lymphocytic B-cell lymphoma involving skin (disorder)
- Smoldering chronic lymphocytic leukemia (disorder)
- Smoldering myeloma (disorder)
- Solitary osseous myeloma (disorder)

What constitutes an exclusion for measles, mumps, and/or rubella vaccination (Numerator 3)? (SNOMED-CT)

- Specific antibody deficiency (disorder)
- Specific skin infiltration in Hodgkin's disease (disorder)
- Splenic lymphoma with villous lymphocytes (disorder)
- Spongiotic mycosis fungoides (disorder)
- Stress neutrophilia (disorder)
- Subacute leukemia (disorder)
- Subacute leukemia in remission (disorder)
- Subacute lymphoid leukemia (disorder)
- Subacute lymphoid leukemia in remission (disorder)
- Subacute monocytic leukemia (disorder)
- Subacute myeloid leukemia (disorder)
- Subacute myeloid leukemia in remission (disorder)
- Subacute myelomonocytic leukemia (disorder)
- Subcutaneous panniculitic cutaneous T-cell lymphoma (disorder)
- T-cell acute lymphoblastic leukemia (disorder)
- T-cell acute lymphoblastic leukemia in remission (disorder)
- T-cell AND/OR NK-cell neoplasm (disorder)
- T-cell chronic lymphocytic leukemia (disorder)
- T-cell lymphoma (disorder)
- T-cell prolymphocytic leukemia (disorder)
- Terminal component deficiency (disorder)
- Thymic aplasia or dysplasia with immunodeficiency (disorder)
- T-lymphocyte immunodeficiency (disorder)
- Toxic neutropenia (disorder)
- Transient hypogammaglobulinemia of infancy (disorder)
- Transient immunodeficiency of infancy (disorder)
- Transient neonatal neutropenia (disorder)
- Triple X syndrome, epilepsy, and hypogammaglobulinemia (disorder)
- Tuftsin deficiency (disorder)
- Tumor stage mycosis fungoides (disorder)
- T-zone lymphoma (disorder)
- Warts, hypogammaglobulinemia, infections, and myelokathexis (disorder)
- Wiskott-Aldrich autosomal dominant variant syndrome (disorder)
- Wiskott-Aldrich syndrome (disorder)
- X-linked agammaglobulinemia (disorder)
- X-linked agammaglobulinemia with growth hormone deficiency (disorder)
- X-linked hypogammaglobulinemia (disorder)
- X-linked lymphoproliferative syndrome (disorder)
- X-linked severe combined immunodeficiency (disorder)

EXCLUSION OR EXCEPTION CRITERIA (NUMERATOR 4)

What constitutes an exclusion for HiB Vaccination (Numerator 4)? (RxNorm)

- Haemophilus capsular oligosaccharide 0.02 MG/ML / Tetanus Toxoid Vaccine 0.048 MG/ML Injectable Solution
- Haemophilus influenzae b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.068 MG/ML Injectable Solution
- 0.5 ML Haemophilus influenzae b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.068 MG/ML Injectable Solution
- Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine 0.265 MG/ML / Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension
- Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine 0.265 MG/ML Injectable Suspension
- Haemophilus b polysaccharide vaccine 0.02 MG/ML

What constitutes an exclusion for Hepatitis B Vaccination (Numerator 5)? (RxNorm)

- Baker's yeast allergenic extract 100 MG/ML injectable solution
- Baker's yeast (Saccharomyces cerevisiae) allergenic extract 50 MG/ML Injectable Solution
- Hepatitis B Vaccine 0.01 MG/ML Injectable Suspension
- Hepatitis B Vaccine 0.02 MG/ML Injectable Suspension
- Hepatitis B Vaccine 0.04 MG/ML Injectable Suspension
- Hepatitis A Vaccine, Inactivated 720 UNT/ML / Hepatitis B Vaccine 0.02 MG/ML Injectable Suspension
- 0.5 ML Hepatitis B Vaccine 0.02 MG/ML Prefilled Syringe

What constitutes an exclusion for Hepatitis B Vaccination (Numerator 5)? (SNOMED-CT)

- Cerevisin

EXCLUSION OR EXCEPTION CRITERIA (NUMERATOR 6)

What constitutes an exclusion for VZV Vaccination (Numerator 6)? (RxNorm)

- Varicella-zoster immune globulin 50 mg/ml injectable solution
- Varicella-zoster immune globulin 100 unt/ml injectable solution
- Varicella-zoster immune globulin 50 unt/ml injectable solution

What constitutes an exclusion for VZV Vaccination (Numerator 6)? (ICD-9-CM)

- See exclusion for measles, mumps and/or rubella (Numerator 3)

What constitutes an exclusion for VZV Vaccination (Numerator 6)? (ICD-10-CM)

- See exclusion for measles, mumps and/or rubella (Numerator 3)

What constitutes an exclusion for VZV Vaccination (Numerator 6)? (SNOMED-CT)

- See exclusion for measles, mumps and/or rubella (Numerator 3)

EXCLUSION OR EXCEPTION CRITERIA (NUMERATOR 7)

What constitutes an exclusion for PCV Vaccination (Numerator 7)? (RxNorm)

- Pneumococcal capsular polysaccharide type 1 vaccine 0.05 MG/ML
- Pneumococcal capsular polysaccharide type 10A vaccine 0.05 MG/ML
- Pneumococcal capsular polysaccharide type 11A vaccine 0.05 MG/ML
- Pneumococcal capsular polysaccharide type 12F vaccine 0.05 MG/ML
- Pneumococcal capsular polysaccharide type 14 vaccine 0.05 MG/ML
- Pneumococcal capsular polysaccharide type 15B vaccine 0.05 MG/ML
- Pneumococcal capsular polysaccharide type 17F vaccine 0.05 MG/ML
- Pneumococcal capsular polysaccharide type 18C vaccine 0.05 MG/ML
- Pneumococcal capsular polysaccharide type 19A vaccine 0.05 MG/ML
- Pneumococcal capsular polysaccharide type 19F vaccine 0.05 MG/ML
- Pneumococcal capsular polysaccharide type 2 vaccine 0.05 MG/ML
- Pneumococcal capsular polysaccharide type 20 vaccine 0.05 MG/ML
- Pneumococcal capsular polysaccharide type 22F vaccine 0.05 MG/ML
- Pneumococcal capsular polysaccharide type 23F vaccine 0.05 MG/ML
- Pneumococcal capsular polysaccharide type 3 vaccine 0.05 MG/ML
- Pneumococcal capsular polysaccharide type 33F vaccine 0.05 MG/ML
- Pneumococcal capsular polysaccharide type 4 vaccine 0.05 MG/ML
- Pneumococcal capsular polysaccharide type 5 vaccine 0.05 MG/ML
- Pneumococcal capsular polysaccharide type 6B vaccine 0.05 MG/ML
- Pneumococcal capsular polysaccharide type 7F vaccine 0.05 MG/ML
- Pneumococcal capsular polysaccharide type 8 vaccine 0.05 MG/ML
- Pneumococcal capsular polysaccharide type 9N vaccine 0.05 MG/ML
- Pneumococcal capsular polysaccharide type 9V vaccine 0.05 MG/ML
- Pneu. capsular polysaccharide type 1 vacc. 0.05 mg/mL /Pneu. capsular polysaccharide type 10A vacc. 0.05 mg/mL /Pneu. capsular polysaccharide type 11A vacc. 0.05 mg/mL /Pneu. capsular polysaccharide type 12F vacc 0.05 mg/mL /Pneu. capsular polysaccharide type 14 vacc 0.05 mg/mL /Pneu. capsular polysaccharide type 15B vacc 0.05 mg/mL /Pneu. capsular polysaccharide type 17F vacc 0.05 mg/mL /Pneu. capsular polysaccharide type 18C vacc 0.05 mg/mL /Pneu. capsular polysaccharide type 19A vacc. 0.05 mg/mL /Pneu. capsular polysaccharide type 19F vacc. 0.05 mg/mL /Pneu. capsular polysaccharide type 2 vacc 0.05 mg/mL /Pneu. capsular polysaccharide type 20 vacc 0.05 mg/mL /Pneu. capsular polysaccharide type 22F vacc. 0.05 mg/mL /Pneu. capsular polysaccharide type 23F vacc. 0.05 mg/mL /Pneu. capsular polysaccharide type 3 vacc. 0.05 mg/mL /Pneu. capsular polysaccharide type 33F vacc. 0.05 mg/mL /Pneu. capsular polysaccharide type 4 vacc 0.05 mg/mL /Pneu. capsular polysaccharide type 5 vacc 0.05 mg/mL /Pneu. capsular polysaccharide type 6B vacc 0.05 mg/mL /Pneu. capsular polysaccharide type 7F vacc 0.05 mg/mL /Pneu. capsular polysaccharide type 8 vacc 0.05 mg/mL /Pneu. capsular polysaccharide type 9N vacc. 0.05 mg/mL /Pneu. capsular polysaccharide type 9V vacc 0.05 mg/mL Injectable Solution

EXCLUSION OR EXCEPTION CRITERIA (NUMERATOR 8)

What constitutes an exclusion for Hepatitis A vaccination (Numerator 8)? (RxNorm)

- Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Injectible Suspension
- 1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe
- 0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe

What constitutes an exclusion for Hepatitis A vaccination (Numerator 8)? (RxNorm)

- Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension
- 1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe

EXCLUSION OR EXCEPTION CRITERIA (NUMERATOR 9)

What constitutes an exclusion for rotavirus vaccination (Numerator 9)? (RxNorm)

- Human-Bovine Reassortant Rotavirus Strain G1 Vaccine 1100000 UNT/ML / Human-Bovine Reassortant Rotavirus Strain G2 Vaccine 1400000 UNT/ML / Human-Bovine Reassortant Rotavirus Strain G3 Vaccine 1100000 UNT/ML / Human-Bovine Reassortant Rotavirus Strain G4 Vaccine 1000000 UNT/ML / Human-Bovine Reassortant Rotavirus Strain P1A[8] Vaccine 1150000 UNT/ML Oral Suspension
- Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 1000000 UNT/ML Oral Suspension

EXCLUSION OR EXCEPTION CRITERIA (NUMERATOR 10)

What constitutes an exclusion for influenza vaccination (Numerator 10)? (RxNorm)

- Influenza Virus Vaccine, Inactivated A-Brisbane-10-2007 (H3N2)-like virus (A-Uruguay-716-2007 NYMC X-175C) strain 0.03 MG/ML / Influenza Virus Vaccine, Inactivated A-Brisbane-59-2007 (H1N1)-like virus (A-Brisbane-59-2007 IVR-148) strain 0.03 MG/ML / Influenza Virus Vaccine, Inactivated, B-Florida-4-2006-like virus (B-Florida-4-2006) strain 0.03 MG/ML Injectable Suspension
- 0.5 ML Influenza Virus Vaccine, Inactivated A-Brisbane-10-2007 (H3N2)-like virus (A-Uruguay-716-2007 NYMC X-175C) strain 0.03 MG/ML / Influenza Virus Vaccine, Inactivated A-Brisbane-59-2007 (H1N1)-like virus (A-Brisbane-59-2007 IVR-148) strain 0.03 MG/ML / Influenza Virus Vaccine, Inactivated, B-Florida-4-2006-like virus (B-Florida-4-2006) strain 0.03 MG/ML Prefilled Syringe
- Influenza Virus Vaccine, Live Attenuated, A-South Dakota-6-2007 (H1N1) (A-Brisbane-59-2007-like) strain 158000000 UNT/ML / Influenza Virus Vaccine, Live Attenuated, A-Uruguay-716-2007 (H3N2) (A-Brisbane-10-2007-like) strain 158000000 UNT/ML / Influenza Virus Vaccine, Live Attenuated, B-Florida-4-2006 strain 158000000 UNT/ML Nasal Spray
- 0.25 ML Influenza Virus Vaccine, Inactivated A-Brisbane-59-2007 (H1N1) strain 0.03 MG/ML / Influenza Virus Vaccine, Inactivated A-Uruguay-716-2007 (H3N2) (A-Brisbane-10-2007-like) strain 0.03 MG/ML / Influenza Virus Vaccine, Inactivated B-Florida-4-2006 strain 0.03 MG/ML Prefilled Syringe
- 0.5 ML Influenza Virus Vaccine, Inactivated A-Brisbane-59-2007, IVR-148 (H1N1) strain 0.03 MG/ML / Influenza Virus Vaccine, Inactivated A-Uruguay-716-2007, NYMC X-175C (H3N2) strain 0.03 MG/ML / Influenza Virus Vaccine, Inactivated B-Brisbane-60-2008 strain 0.03 MG/ML Prefilled Syringe
- 0.25 ML Influenza Virus Vaccine, Inactivated A-Brisbane-59-2007, IVR-148 (H1N1) strain 0.03 MG/ML / Influenza Virus Vaccine, Inactivated A-Uruguay-716-2007, NYMC X-175C (H3N2) strain 0.03 MG/ML / Influenza Virus Vaccine, Inactivated B-Brisbane-60-2008 strain 0.03 MG/ML Prefilled Syringe
- 0.25 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML Prefilled Syringe
- 0.5 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML Prefilled Syringe
- 0.2 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 158000000 UNT/ML Nasal Spray

What constitutes an exclusion for influenza vaccination (Numerator 10)? (ICD-9-CM)

- See exclusions for measles, mumps, and /or rubella (Numerator 3)

What constitutes an exclusion for influenza vaccination (Numerator 10)? (ICD-10-CM)

- See exclusions for measles, mumps, and /or rubella (Numerator 3)

What constitutes an exclusion for influenza vaccination (Numerator 10)? (SNOMED-CT)

- See exclusions for measles, mumps, and /or rubella (Numerator 3)

EXCLUSION OR EXCEPTION CRITERIA (NUMERATOR 11 & 12)

For numerator 11, see exclusion criteria for numerators 1-6

For numerator 12, see exclusion criteria for numerators 1-7

TYPES OF CODES REQUIRED FROM YOUR EHR FOR CALCULATING THIS CLINICAL QUALITY MEASURE

NQF0038	CPT	CPT Modifier	CVX	Grouping	HCPCS	HL7	ICD-9*	ICD-10	LOINC	RxNorm	SNOMED*
Numerator ¹	x			x							x
Denominator ²				x							
Exceptions or exclusions ³											x

- Codes with an asterisk (*) are required from certified EHRs
- ¹ To identify the numerator in this CQM, the following standard codes are required: one "physical exam" code from LOINC or SNOMED AND/OR a "communication" code from SNOMED OR "care goal" code from CPT, HCPCS, ICD-9, SNOMED or GROUPING.
- ² To identify the denominator in this CQM, the following standard codes are required: an "individual characteristic" code from HL7, AND an "encounter" code from CPT, HCPCS, or Grouping.
- ³ To identify the exclusions in this CQM, the following standard codes are required: an "individual characteristic" code from SNOMED, OR a "diagnosis/condition/problem" code from ICD-9, SNOMED or Grouping, OR a "negation rationale" code from HL7.

Abbreviation	Long Name	Definition/Description
CPT	Current Procedural Terminology	The CPT (Current Procedural Terminology) is produced by the American Medical Association (AMA). CPT codes are used to report medical procedures and services. (Source: CDC)
CVX	Codes for Vaccine Administered	This vocabulary provides terminology for Vaccine Administered. The vocabulary is defined in Health Level Seven (HL7) Version 2.5.1. (Source: USHIK)
HCPCS	Healthcare Common Procedure Coding System	Level I of the HCPCS is comprised of CPT (Current Procedural Terminology), a numeric coding system maintained by the American Medical Association (AMA). Level II of the HCPCS is a standardized coding system that is used primarily to identify products, supplies, and services not included in the CPT codes, such as ambulance services and durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS) when used outside a physician's office. (Source: CMS)

Abbreviation	Long Name	Definition/Description
HL7	Health Level Seven	HL7 is an accredited ANSI standard organization that produces the HL7 messaging standard. It is the accepted messaging standard for communicating clinical data. It is supported by every major medical informatics system vendor in the US. (Source: ASPE)
ICD-9	International Statistical Classification of Diseases and Related Health Problems, 9th revision	The International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) is based on the World Health Organization's Ninth Revision, International Classification of Diseases (ICD-9). ICD-9-CM is the official system of assigning codes to diagnoses and procedures associated with hospital utilization in the United States. The ICD-9 is used to code and classify mortality data from death certificates. (Source: CDC)
ICD-10	International Statistical Classification of Diseases and Related Health Problems, 10th revision	The International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10), published by the World Health Organization (WHO), is the foundation of ICD-10-CM. ICD-10 continues to be the classification used in cause-of-death coding in the United States. The ICD-10-CM is comparable with the ICD-10 (Source: CDC)
LOINC	Logical Observation Identifiers Names and Codes	A universal code system for identifying laboratory and clinical observations. (Source: LOINC)
RxNorm	RxNorm	RxNorm provides normalized names for clinical drugs and links its names to many of the drug vocabularies commonly used in pharmacy management and drug interaction software, including those of First Databank, Micromedex, MediSpan, Gold Standard Alchemy, and Multum. By providing links between these vocabularies, RxNorm can mediate messages between systems not using the same software and vocabulary. (Source: NLM NIH)
SNOMED-CT	Systematic Nomenclature of Medicine - Clinical Terms	SNOMED CT (Systematized Nomenclature of Medicine--Clinical Terms) is a comprehensive clinical terminology, originally created by the College of American Pathologists (CAP) and, as of April 2007, owned, maintained, and distributed by the International Health Terminology Standards Development Organisation (IHTSDO), a not-for-profit association in Denmark. (Source: NLM NIH)

THE MEASURES AND SPECIFICATIONS ARE PROVIDED “AS IS” WITHOUT WARRANTY OF ANY KIND

© 2010 American Medical Association and /or National Committee for Quality Assurance. All Rights Reserved.

Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AMA, NCQA, the PCPI and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications.

CPT® contained in the Measure specifications is copyright 2004- 2010 American Medical Association. LOINC® copyright 2004 Regenstrief Institute, Inc. This material contains SNOMED Clinical Terms® (SNOMED CT®) copyright 2004-2010 International Health Terminology Standards Development Organisation. All Rights Reserved.